Know Labs (KNWN) S-1/A 17 Aug 22 IPO registration (amended) Financial data

Cover

Cover	9 Months Ended
	Jun. 30, 2022
Cover [Abstract]
Entity Registrant Name	Know Labs, Inc.
Entity Central Index Key	0001074828
Document Type	S-1/A
Amendment Flag	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	90-0273142
Entity Address Address Line 1	500 Union Street
Entity Address Address Line 2	Suite 810
Entity Address City Or Town	Seattle
Entity Address State Or Province	WA
Entity Address Postal Zip Code	98101
City Area Code	206
Local Phone Number	903-1351

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 8,351,945	$ 12,258,218	$ 4,298,179
Accounts receivable- related party	46,146
Total current assets	8,398,091	12,258,218	4,298,179
PROPERTY AND EQUIPMENT, NET	953,378	328,504	128,671
OTHER ASSETS
Other assets	13,767	13,767	25,180
Intangible assets		0	101,114
Operating lease right of use asset	262,242	289,002	129,003
TOTAL ASSETS	9,627,478	12,889,491	4,682,147
CURRENT LIABILITIES:
Accounts payable - trade	405,423	419,093	493,497
Accrued expenses	533,993	893,137	401,178
Accrued expenses - related parties	1,270,652	421,599	591,600
Notes payable- PPP loans, current		431,803	0
Convertible notes payable, net	2,255,066	9,191,155	3,967,578
Simple Agreements for Future Equity		0	785,000
Current portion of operating lease right of use liability	145,815	112,371	108,779
Total current liabilities	4,610,949	11,469,158	6,347,632
NON-CURRENT LIABILITIES:
Notes payable- PPP loans		431,803	226,170
Operating lease right of use liability, net of current portion	97,261	178,170	23,256
Total non-current liabilities	97,261	609,973	249,426
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock	0	0	0
Common stock - $0.001 par value, 200,000,000 shares authorized, 43,802,147 and 35,166,551 shares issued and outstanding at 6/30/2022 and 9/30/2021, respectively	43,803	35,168	24,807
Additional paid in capital	100,699,797	82,530,684	54,023,758
Accumulated deficit	(95,827,137)	(81,326,494)	(55,966,281)
Total stockholders' equity	4,919,268	1,242,163	(1,914,911)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	9,627,478	12,889,491	4,682,147
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock	1,790	1,790	1,790
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock	$ 1,015	$ 1,015	$ 1,015

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Preferred stock par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock shares issued	0	0	0
Preferred stock shares outstanding	0	0	0
Common stock par value	$ 0.001	$ 0.001	$ 0.001
Common stock shares authorized	200,000,000	100,000,000	100,000,000
Common stock shares issued	43,802,147	35,166,551	24,804,874
Common stock shares outstanding	43,802,147	35,166,551	24,804,874
Convertible Preferred Stock Series C [Member]
Preferred stock par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock shares authorized	1,785,715	1,785,715	1,785,715
Preferred stock shares issued	1,785,715	1,785,715	1,785,715
Preferred stock shares outstanding	1,785,715	1,785,715	1,785,715
Series D Convertible Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock shares authorized	1,016,014	1,016,014	1,016,014
Preferred stock shares issued	1,016,004	1,016,004	1,016,004
Preferred stock shares outstanding	1,016,004	1,016,004	1,016,004

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS
REVENUE	$ 0	$ 0	$ 4,360,087	$ 0	$ 0	$ 121,939
COST OF SALES					0	69,726
GROSS PROFIT					0	52,213
OPERATING EXPENSES-
RESEARCH AND DEVELOPMENT EXPENSES	1,272,537	868,584	3,406,996	3,094,123	3,969,972	2,033,726
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	1,588,823	994,221	4,253,997	4,934,085	6,476,176	4,844,415
SELLING AND TRANSACTIONAL COSTS FOR DIGITAL ASSETS	164,093	0	3,436,955	0
Total operating expenses	3,025,453	1,862,805	11,097,948	8,028,208
OPERATING LOSS	(3,025,453)	(1,862,805)	(6,737,861)	(8,028,208)	(10,446,148)	(6,825,928)
OTHER INCOME (EXPENSE):
Interest expense	(239,760)	(5,228,058)	(8,024,709)	(9,735,604)	(14,914,065)	(6,094,682)
Other income	261,927	0	261,927	0	0	65,769
(Loss) on debt settlements					0	(707,800)
Total other (expense), net	22,167	(5,228,058)	(7,762,782)	(9,735,604)	(14,914,065)	(6,736,713)
LOSS BEFORE INCOME TAXES	(3,003,286)	(7,090,863)	(14,500,643)	(17,763,812)	(25,360,213)	(13,562,641)
Income tax expense	0	0	0	0	0	0
NET LOSS	$ (3,003,286)	$ (7,090,863)	$ (14,500,643)	$ (17,763,812)	$ (25,360,213)	$ (13,562,641)
Basic and diluted loss per share	$ (0.07)	$ (0.23)	$ (0.37)	$ (0.64)	$ (0.86)	$ (0.62)
Weighted average shares of common stock outstanding- basic and diluted	43,760,904	31,052,229	39,032,860	27,651,679	29,370,596	21,791,058

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)	Total	Convertible Preferred Stock Series C [Member]	Series D Convertible Preferred Stock [Member]	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Series C Convertibles Preferred Stock Member
Balance, shares at Sep. 30, 2019		1,785,715	1,016,004	18,366,178
Balance, amount at Sep. 30, 2019	$ (3,297,290)	$ 1,790	$ 1,015	$ 18,366	$ 39,085,179	$ (42,403,640)
Stock compensation expense - employee options	1,702,085	0	0	$ 0	1,702,085	0
Stock option exercise, shares				73,191
Stock option exercise, amount	$ 0	0	0	$ 73	$ (73)	0
Conversion of debt offering and accrued interest (Note 7), shares	975,326			4,581,917	975,326
Conversion of debt offering and accrued interest (Note 7), amount	$ 4,596,537	0	0	$ 4,585	$ 4,591,952	0
Beneficial conversion feature (Note 7)	3,766,074	0	0	0	3,766,074	0
Issuance of warrants to debt holders (Note 7)	1,824,998	0	0	$ 0	1,824,998	0
Issuance of common stock for services, shares				550,000
Issuance of common stock for services, amount	1,045,000	0		$ 550	1,044,450	0
Issuance of common stock for exercise of warrants, shares				733,588
Issuance of common stock for exercise of warrants, amount	85,000	0	0	$ 733	84,267	0
Issuance of shares related to Settlement and Mutual Release and Subscription Agreements, shares				500,000
Issuance of shares related to Settlement and Mutual Release and Subscription Agreements, amount	950,000	0	0	$ 500	949,500	0
Net loss	(13,562,641)	$ 0	$ 0	$ 0	0	(13,562,641)
Balance, shares at Sep. 30, 2020		1,785,715	1,016,004	24,804,874			1,785,715
Balance, amount at Sep. 30, 2020	(1,914,911)	$ 1,790	$ 1,015	$ 24,807	54,023,758	(55,966,281)	$ 1,790
Stock compensation expense - employee options	175,442		0	$ 0	175,442	0	0
Conversion of debt offering and accrued interest (Note 7), shares				561,600
Conversion of debt offering and accrued interest (Note 7), amount	561,600			$ 562	561,038
Issuance of common stock for exercise of warrants, shares				3,750
Issuance of common stock for exercise of warrants, amount	4,688		0	$ 4	4,684	0	0
Net loss	(5,299,331)		0	0	0	(5,299,331)	0
Issuance of warrant for services to related party	1,811,691		0	0	1,811,691	0	0
Conversion of debt offering and accrued interest (Note 7), amount	561,600		$ 0	$ 562	561,038	0	$ 0
Balance, shares at Dec. 31, 2020		1,785,715	1,016,004	25,370,224			1,785,715
Balance, amount at Dec. 31, 2020	(4,660,822)	$ 1,790	$ 1,015	$ 25,372	56,576,613	(61,265,612)	$ 1,790
Balance, shares at Sep. 30, 2020		1,785,715	1,016,004	24,804,874			1,785,715
Balance, amount at Sep. 30, 2020	(1,914,911)	$ 1,790	$ 1,015	$ 24,807	54,023,758	(55,966,281)	$ 1,790
Beneficial conversion feature (Note 7)	9,769,683
Issuance of warrants to debt holders (Note 7)	4,439,317
Net loss	(17,763,812)
Balance, shares at Jun. 30, 2021			1,016,004	33,719,669			1,785,715
Balance, amount at Jun. 30, 2021	5,999,754		$ 1,015	$ 33,720	79,693,322	(73,730,093)	$ 1,790
Balance, shares at Sep. 30, 2020		1,785,715	1,016,004	24,804,874			1,785,715
Balance, amount at Sep. 30, 2020	(1,914,911)	$ 1,790	$ 1,015	$ 24,807	54,023,758	(55,966,281)	$ 1,790
Stock compensation expense - employee options	1,028,522	0	0	$ 0	1,028,522	0
Conversion of debt offering and accrued interest (Note 7), shares				6,090,660
Conversion of debt offering and accrued interest (Note 7), amount	6,098,058	0	0	$ 6,091	6,091,968	0
Beneficial conversion feature (Note 7)	9,769,683	0	0	0	9,769,683	0
Issuance of warrants to debt holders (Note 7)	4,439,317	0	0	$ 0	4,439,317	0
Issuance of common stock for services, shares				97,000
Issuance of common stock for services, amount	202,820	0	0	$ 97	202,723	0
Issuance of common stock for exercise of warrants, shares				3,676,542
Issuance of common stock for exercise of warrants, amount	1,313,203	0	0	$ 3,675	1,309,528	0
Net loss	(25,360,213)	0	0	0	0	(25,360,213)
Issuance of warrant for services	2,547,436	0	0	0	2,547,436	0
Issuance of warrants for services related to debt offering (Note 7), amount	1,667,281	0	0	$ 0	1,667,281	0
Issuance of common stock for stock option exercises, shares				16,875
Issuance of common stock for stock option exercises, amount	23,344	0	0	$ 17	23,327	0
Issuance of shares and warrants for conversion of Simple Agreements for Future Equity, shares				480,600
Issuance of shares and warrants for conversion of Simple Agreements for Future Equity, amount	1,427,622	$ 0	$ 0	$ 481	1,427,141	0
Balance, shares at Sep. 30, 2021		1,785,715	1,016,004	35,166,551			1,785,715
Balance, amount at Sep. 30, 2021	1,242,163	$ 1,790	$ 1,015	$ 35,168	82,530,684	(81,326,494)	$ 1,790
Balance, shares at Dec. 31, 2020		1,785,715	1,016,004	25,370,224			1,785,715
Balance, amount at Dec. 31, 2020	(4,660,822)	$ 1,790	$ 1,015	$ 25,372	56,576,613	(61,265,612)	$ 1,790
Stock compensation expense - employee options	127,407		0	$ 0	127,407	0	0
Conversion of debt offering and accrued interest (Note 7), shares				210,600
Beneficial conversion feature (Note 7)	9,769,683		0	$ 0	9,769,683	0	0
Issuance of common stock for exercise of warrants, shares				2,579,643
Issuance of common stock for exercise of warrants, amount	648,516		0	$ 2,578	645,938	0	0
Net loss	(5,373,618)		0	0	0	(5,373,618)	0
Issuance of warrant for services to related party	382,566		0	0	382,566	0	0
Conversion of debt offering and accrued interest (Note 7), amount	210,606		0	211	210,395	0	0
Issuance of warrants to debt holders (Note 7)	4,439,317		0	0	4,439,317	0	0
Issuance of warrants for services related to debt offering (Note 7)	1,667,281		0	$ 0	1,667,281	0	0
Issuance of common stock for services, shares				97,000
Issuance of common stock for services, amount	202,820		$ 0	$ 97	202,723	0	$ 0
Balance, shares at Mar. 31, 2021		1,785,715	1,016,004	28,257,467			1,785,715
Balance, amount at Mar. 31, 2021	7,413,756	$ 1,790	$ 1,015	$ 28,258	74,021,923	(66,639,230)	$ 1,790
Stock compensation expense - employee options	267,665		0	$ 0	267,665	0	0
Conversion of debt offering and accrued interest (Note 7), shares				5,318,460
Conversion of debt offering and accrued interest (Note 7), amount	210,606			$ 211	210,395
Beneficial conversion feature (Note 7)	9,769,683				9,769,683
Issuance of common stock for exercise of warrants, shares				126,867
Issuance of common stock for exercise of warrants, amount	60,000		0	$ 127	59,873	0	0
Net loss	(7,090,863)		0	0	0	(7,090,863)	0
Issuance of warrant for services to related party	382,566				382,566
Conversion of debt offering and accrued interest (Note 7), amount	5,325,853		0	$ 5,318	5,320,535	0	0
Issuance of common stock for stock option exercises, shares				16,875
Issuance of common stock for stock option exercises, amount	23,344		$ 0	$ 17	23,327	0	$ 0
Issuance of warrants to debt holders (Note 7)	4,439,317				4,439,317
Issuance of warrants for services related to debt offering (Note 7)	1,667,281				1,667,281
Issuance of common stock for services, shares				97,000
Issuance of common stock for services, amount	202,820			$ 97	202,723
Balance, shares at Jun. 30, 2021			1,016,004	33,719,669			1,785,715
Balance, amount at Jun. 30, 2021	5,999,754		$ 1,015	$ 33,720	79,693,322	(73,730,093)	$ 1,790
Balance, shares at Sep. 30, 2021		1,785,715	1,016,004	35,166,551			1,785,715
Balance, amount at Sep. 30, 2021	1,242,163	$ 1,790	$ 1,015	$ 35,168	82,530,684	(81,326,494)	$ 1,790
Stock compensation expense - employee options	204,170		0	$ 0	204,170	0	0
Issuance of common stock for exercise of warrants, shares				801,486
Issuance of common stock for exercise of warrants, amount	766,486		0	$ 801	765,685	0	0
Net loss	(5,356,619)		0	$ 0	0	(5,356,619)	0
Issuance of common stock for stock option exercises, shares				1,875
Issuance of common stock for stock option exercises, amount	2,344		$ 0	$ 2	2,342	0	$ 0
Balance, shares at Dec. 31, 2021		1,785,715	1,016,004	35,969,912			1,785,715
Balance, amount at Dec. 31, 2021	(3,141,456)	$ 1,790	$ 1,015	$ 35,971	83,502,881	(86,683,113)	$ 1,790
Balance, shares at Sep. 30, 2021		1,785,715	1,016,004	35,166,551			1,785,715
Balance, amount at Sep. 30, 2021	1,242,163	$ 1,790	$ 1,015	$ 35,168	82,530,684	(81,326,494)	$ 1,790
Beneficial conversion feature (Note 7)	0
Net loss	(14,500,643)
Modification of warrant-interest expense	244,260
Balance, shares at Jun. 30, 2022		1,785,715	1,016,004	43,802,147			1,785,715
Balance, amount at Jun. 30, 2022	4,919,268	$ 1,790	$ 1,015	$ 43,803	100,699,797	(92,823,851)	$ 1,790
Balance, shares at Dec. 31, 2021		1,785,715	1,016,004	35,969,912			1,785,715
Balance, amount at Dec. 31, 2021	(3,141,456)	$ 1,790	$ 1,015	$ 35,971	83,502,881	(86,683,113)	$ 1,790
Stock compensation expense - employee options	432,481		0	$ 0	432,481	0	0
Conversion of debt offering and accrued interest (Note 7), shares				7,672,860
Net loss	(6,140,738)		0	$ 0	0	(6,140,738)	0
Issuance of warrant for services to related party	71,220		0	0	71,220	0	0
Conversion of debt offering and accrued interest (Note 7), amount	15,345,720		0	$ 7,673	15,338,047	0	0
Issuance of common stock for stock option exercises, shares				5,000
Issuance of common stock for stock option exercises, amount	9,000		0	$ 5	8,995	0	0
Issuance of common stock for services, shares				90,000
Issuance of common stock for services, amount	153,000		$ 0	$ 90	152,910	0	$ 0
Balance, shares at Mar. 31, 2022			1,016,004	43,737,772			1,785,715
Balance, amount at Mar. 31, 2022	6,729,227		$ 1,015	$ 43,739	99,506,534	(92,823,851)	$ 1,790
Stock compensation expense - employee options	919,224		0	$ 0	919,224	0	0
Conversion of debt offering and accrued interest (Note 7), shares				7,672,860
Conversion of debt offering and accrued interest (Note 7), amount	15,345,720			$ 7,673	15,338,047
Issuance of common stock for exercise of warrants, shares				62,500
Issuance of common stock for exercise of warrants, amount	27,500		0	$ 62	27,438	0	0
Net loss	(3,003,286)		0	$ 0	0	(3,003,286)	0
Issuance of warrant for services to related party	71,220				71,220
Issuance of common stock for stock option exercises, shares				1,875
Issuance of common stock for stock option exercises, amount	2,343		0	$ 2	2,341	0	0
Issuance of common stock for services, shares				90,000
Issuance of common stock for services, amount	153,000			$ 90	152,910
Modification of warrant-interest expense	244,260		$ 0	$ 0	244,260	0	$ 0
Balance, shares at Jun. 30, 2022		1,785,715	1,016,004	43,802,147			1,785,715
Balance, amount at Jun. 30, 2022	$ 4,919,268	$ 1,790	$ 1,015	$ 43,803	$ 100,699,797	$ (92,823,851)	$ 1,790

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (14,500,643)	$ (17,763,812)	$ (25,360,213)	$ (13,562,641)
operating activities
Depreciation and amortization	218,683	166,094	200,807	242,987
Issuance of common stock for services	153,000	202,820	23,344	0
Issuance of common stock warrants for services	71,220	0	202,820	1,045,000
Modification of warrant-interest expense	244,260
Stock based compensation- warrants		2,194,257
Stock based compensation- stock option grants	1,555,875	570,514	1,028,522	1,702,085
Gain on forgiveness of notes payable - PPP loans	(252,700)
Right of use, net	(20,705)	(1,853)	(1,493)	422
Amortization of debt discount to interest expense	7,272,911	9,071,592	13,722,672	5,662,690
Changes in operating assets and liabilities:
Accounts receivable- related party	46,146
Other long-term assets		11,413	(11,413)	11,414
Accounts payable - trade and accrued expenses	(1,612,959)	404,469	797,337	218,018
Provision on loss on accounts receivable		634
NET CASH (USED IN) OPERATING ACTIVITIES	(3,691,286)	(5,144,506)	(6,850,699)	(3,913,803)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of research and development equipment	(843,557)	(47,553)	(299,525)	(70,134)
NET CASH (USED IN) INVESTING ACTIVITIES:	(843,557)	(74,553)	(299,525)	(70,134)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes payable	0	14,209,000	14,209,000	5,639,500
Payments for issuance costs from notes payable		(727,117)	(727,117)	(479,965)
Proceeds from Simple Agreements for Future Equity	0	340,000	340,000	785,000
Settlement of notes payable- PPP loans	(179,103)
Proceeds from note payable - PPP	0	205,633	205,633	226,170
Repayment from Simple Agreements for Future Equity			(253,800)	0
Proceeds from issuance of shares related to debt settlement			0	125,000
Proceeds from issuance of common stock for stock options exercise	13,687	23,344
Proceeds from issuance of common stock for warrant exercise	793,986	713,203	1,313,203	85,575
NET CASH PROVIDED BY FINANCING ACTIVITIES	628,570	14,764,063	15,110,263	6,381,280
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(3,906,273)	9,572,004	7,960,039	2,397,343
CASH AND CASH EQUIVALENTS, beginning of period	12,258,218	4,298,179	4,298,179	1,900,836
CASH AND CASH EQUIVALENTS, end of period	8,351,945	13,870,183	12,258,218	4,298,179
Supplemental disclosures of cash flow information:
Interest paid	0	0	18,800	0
Taxes paid	0	0	0	1,922
Non-cash investing and financing activities:
Stock based compensation - warrants			2,547,436	0
Beneficial conversion feature	0	9,769,683	9,769,683	3,766,074
Issuance of warrants for services related to debt offering	0	1,667,281	1,667,281	975,326
Cashless warrant exercise (fair value)		493,601	515,975	111,554
Conversion of debt	14,209,000	5,638,275	5,638,275	4,245,448
Conversion of accrued interest	$ 1,136,720	460,185	460,185	351,089
Loss on sale of assets			0	4,663
(Gain) on debt settlement			0	117,200
Loss related to issuance of shares for debt settlement			0	825,000
Accounts receivable			0	63,049
Prepaid expenses			0	6,435
Inventory			0	7,103
Other long term assets		(11,413)	11,413	(11,414)
Issuance of warrant to debt holders		$ 4,439,317	4,439,317	1,824,998
Cashless stock options exercise (fair value)			0	18,298
Issuance of shares and warrants for conversion of Simple Agreements for Future Equity			$ 1,427,141	$ 0

ORGANIZATION

ORGANIZATION	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
ORGANIZATION
ORGANISATION	1. ORGANIZATION Know Labs, Inc. was incorporated under the laws of the State of Nevada in 1998. The Company currently has authorized 205,000,000 shares of capital stock, of which 200,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share. At the annual shareholder meeting held on October 15, 2021, our authorized shares of common stock was increased to 200,000,000 shares of voting common stock, par value $0.001 per share. Know Labs is focused on the development and commercialization of proprietary biosensor technologies which, when paired with our artificial intelligence, or AI, deep learning platform, are capable of uniquely identifying and measuring almost any material or analyte using electromagnetic energy to detect, record, identify and measure the unique “signature” of said materials or analytes. The Company call these our “Bio-RFID™” technology platform when pertaining to radio and microwave spectroscopy; and “ChromaID” technology platform when pertaining to optical spectroscopy. The data obtained with our biosensor technology is analyzed with our trade secret algorithms which are driven by our AI deep learning platform. There are a significant number of analytes in the human body that relate to health and wellness. The Company’s focus is upon those analytes relating to human health, the identification of which provide diagnostic information and require, by their nature, clearance by the United States Food and Drug Administration. On April 30, 2020, the Company approved and ratified the incorporation of Particle, Inc. Particle is focused on the development and commercialization of our extensive intellectual property relating to electromagnetic energy outside of the medical diagnostic arena which remains the parent company’s singular focus. Since incorporation, Particle has engaged in research and development activities on threaded light bulbs that have a warm white light and can inactivate germs, including bacteria and viruses. It is now looking for partners to take the product to market. On September 17, 2021, the Company incorporated AI Mind, Inc. AI Mind is focused on monetizing the AI Deep Learning Platform. Since incorporation it initially focused on creating graphical images which were sold as Non Fungible Tokens (“NFTs”). During the nine months ended June 30, 2022,	1. ORGANIZATION Know Labs, Inc. (the “Company”) was incorporated under the laws of the State of Nevada in 1998. The Company has authorized 105,000,000 shares of capital stock, of which 100,000,000 are shares of voting common stock, par value 0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share. At the annual shareholder meeting held on October 15, 2021, our authorized shares of common stock was increased to 200,000,000 shares of voting common stock, par value $0.001 per share. The Company is focused on the development and commercialization of proprietary biosensor technologies which, when paired with our AI deep learning platform, are capable of uniquely identifying and measuring almost any material or analyte using electromagnetic energy to detect, record, identify and measure the unique “signature” of said materials or analytes. The Company calls these our “Bio-RFID™” technology platform when pertaining to radio and microwave spectroscopy; and “ChromaID” technology platform when pertaining to optical spectroscopy. The data obtained with the Company’s biosensor technology is analyzed with our trade secret algorithms which are driven by our AI Deep Learning platform. ChromaID is the first technology developed and patented by the Company. For the past several years, the Company has focused upon extensions and new patentable inventions that are derived from and extend beyond our ChromaID technology and intellectual property. The Company calls this technology platform Bio-RFID. The rapid advances made with our Bio-RFID technology in our laboratory have caused us to move quickly into the commercialization phase of our Company as we work to create revenue generating products for the marketplace. Today, the primary focus of the Company is on its Bio-RFID technology, its commercialization and development of related patent assets. Through its wholly owned subsidiary corporations the Company works to exploit additional opportunities and markets that its broad intellectual property and trade secret portfolio addresses. On April 30, 2020, the Company approved and ratified the incorporation of Particle, Inc. Particle is focused on the development and commercialization of our extensive intellectual property relating to electromagnetic energy outside of the medical diagnostic arena which remains the parent company’s singular focus. Since incorporation, Particle has engaged in research and development activities on threaded light bulbs that have a warm white light and can inactivate germs, including bacteria and viruses. It is now looking for partners to take the product to market. On September 17, 2021, the Company approved and ratified the incorporation of AI Mind, Inc. AI Mind is focused on monetizing the AI Deep Learning Platform. Since incorporation it has focused on creating patterns from Company data which were sold as NFTs. The Company will continue to look for opportunities for new applications on its AI Deep Learning Platform to generate revenues to support the continued development of its non-invasive diagnostic technology. In 2010, the Company acquired TransTech Systems, Inc. as an adjunct to the Company’s business. TransTech was a distributor of products for employee and personnel identification and authentication. TransTech historically provided substantially all of the Company’s revenues. The financial results from our TransTech subsidiary had been diminishing as vendors of their products increasingly moved to the Internet and direct sales to their customers. While it did provide our prior year revenues, it was not central to our current focus as a Company. Moreover, the Company wrote down any goodwill associated with its historic acquisition. TransTech ceased operation on June 30, 2020 and was dissolved as of September 30, 2020.

LIQUIDITY and GOING CONCERN

LIQUIDITY and GOING CONCERN	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
LIQUIDITY and GOING CONCERN
LIQUIDITY and GOING CONCERN	2. LIQUIDITY AND GOING CONCERN The Company has cash and cash equivalents of $8,351,945 and net working capital of $6,042,208 (exclusive of convertible notes payable) as of June 30, 2022. The Company anticipates that it will record losses from operations for the foreseeable future. The Company believes that it has enough available cash to operate until June 30, 2023. As of June 30, 2022, the Company’s accumulated deficit was $95,827,137. The Company has had limited capital resources and intends to seek additional cash via equity and debt offerings. On July 29, 2022, the Company filed a Form S-1 registration statement for a proposed new offering of 3 million shares of its common stock with an anticipated offering price of $2.00 per share. Concurrent with, and as a condition to, the offering, Know Labs will apply to uplist its shares to the NYSE American Exchange. The closing of this offering is contingent upon the successful listing of our common stock on NYSE American. The proceeds of warrants currently outstanding, which could be exercised on a cash basis, may generate potential proceeds of up to $16,383,908. If the new offering referenced above is not successful or the warrants are not exercised, the cash conditions may raise substantial doubt about our ability to continue as a going concern. The audit report prepared by the Company’s independent registered public accounting firm relating to our consolidated financial statements for the year ended September 30, 2021 did not include an explanatory paragraph expressing the substantial doubt about the Company’s ability to continue as a going concern.	2. LIQUIDITY The Company has cash of approximately $12,258,218 and net working capital of approximately $10,092,586 (exclusive of convertible notes payable and right of use asset and liabilities) as of September 30, 2021.The Company anticipates that it will record losses from operations for the foreseeable future. The Company believes that it has enough available cash to operate until December 2023. As of September 30, 2021, the Company’s accumulated deficit was $81,326,494. The Company has had limited capital resources and intends to seek additional cash via equity and debt offerings. . On March 15, 2021, the Company closed private placement for gross proceeds of $14,209,000 in exchange for issuing 8% Subordinated Convertible Notes and 3,552,250 Warrants in a private placement to accredited investors, pursuant to a series of substantially identical Securities Purchase Agreements, Common Stock Warrants, and related documents. The Convertible Notes and accrued interest will be automatically converted to Common Stock at $2.00 per share on the one year anniversary starting on March 15, 2022. See Note 15 for discussion of transactions subsequent to September 30, 2021 that generated additional cash for the Company.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS
SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS	3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS Basis of Presentation Principles of Consolidation Cash and Cash Equivalents Equipment Long-Lived Assets Intangible Assets Revenue Recognition · identification of the contract, or contracts, with the customer; · identification of the performance obligations in the contract; · determination of the transaction price; · allocation of the transaction price to the performance obligations in the contract; and · recognition of the revenue when, or as, the Company satisfies a performance obligation. Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. During the nine months ended June 30, 2022, the Company’s artificial intelligence (AI) Deep Learning Platform began generating revenue from digital asset sales of NFT’s. The Company engineering team, using its research date, AI and proprietary algorithms, produced NFT’s in the form of digital art. The NFT’s produced had no recorded cost basis. Digital Asset Sales - After the sale of the NFT, the Ethereum is converted to US dollars as soon as practically possible. The Company records the total value of the gross NFT sale in revenue. Costs incurred in connection with the NFT transaction are recorded in the statement of operations as Selling and Transactional Cost of Digital Assets and include costs to outside consultants, estimated employee and CEO special bonus compensation, digital asset conversion losses and estimated sales and use tax. The amount totaled $164,093 and $3,436,955 for the three and nine months ended June 30, 2022, respectively. Research and Development Expenses The Company’s current research and development efforts are primarily focused on improving our Bio-RFID technology, extending its capacity and developing new and unique applications for this technology. As part of this effort, the Company conducts on-going laboratory testing to ensure that application methods are compatible with the end-user and regulatory requirements, and that they can be implemented in a cost-effective manner. The Company also is actively involved in identifying new applications. The Company’s current internal team along with outside consultants has considerable experience working with the application of the Company’s technologies and their applications. The Company engages third party experts as required to supplement our internal team. The Company believes that continued development of new and enhanced technologies is essential to our future success. The Company incurred expenses of $3,406,996, $3,969,972 and $2,033,726 for the nine months ended June 30, 2022 and the years ended September 30, 2021 and 2020, respectively, on development activities. Advertising Fair Value Measurements and Financial Instruments Fair Value Measurement and Disclosures Level 1 - Quoted prices in active markets for identical assets and liabilities; Level 2 - Inputs other than level one inputs that are either directly or indirectly observable; and. Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of June 30, 2022 and September 30, 2021 are based upon the short-term nature of the assets and liabilities. The Company has a money market account which is considered a level 1 asset. The balance as of June 30, 2022 and September 30, 2021 was $6,041,016 and $12,217,714, respectively. Derivative Financial Instruments - The Company determined that the conversion features for purposes of bifurcation within convertible notes payable were immaterial and there was no derivative liability to be recorded as of June 30, 2022 and September 30, 2021. Stock Based Compensation Convertible Securities Net Loss per Share As of June 30, 2021, the Company had 33,719,669 shares of common stock issued and outstanding. As of June 30, 2021, there were options outstanding for the purchase of 14,650,120 common shares (including unearned stock option grants totaling 11,775,745 shares related to performance targets), warrants for the purchase of 23,169,587 common shares, and 8,108,356 shares of the Company’s common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 16,124,764 common shares (9,020,264 common shares at the current price of $0.25 per share and 7,104,500 common shares at the current price of $2.00 per share) reserved and are issuable upon conversion of convertible debentures of $16,464,066. All of which could potentially dilute future earnings per share but are excluded from the June 30, 2021 calculation of net loss per share because their impact is antidilutive. Comprehensive loss Dividend Policy Use of Estimates Recent Accounting Pronouncements Debt -- debt with Conversion and Other Options (Subtopic470-20) and Derivatives and Hedging --Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity Based on the Company’s review of accounting standard updates issued since the filing of the June 30, 2022 Form 10-Q, there have been no other newly issued or newly applicable accounting pronouncements that have had, or are expected to have, a significant impact on the Company’s consolidated financial statements. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.	3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS Basis of Presentation Principles of Consolidation Cash and Cash Equivalents Equipment Long-Lived Assets Intangible Assets Research and Development Expenses The Company’s current research and development efforts are primarily focused on improving our Bio-RFID technology, extending its capacity and developing new and unique applications for this technology. As part of this effort, the Company conducts on-going laboratory testing to ensure that application methods are compatible with the end-user and regulatory requirements, and that they can be implemented in a cost-effective manner. The Company also is actively involved in identifying new applications. The Company’s current internal team along with outside consultants has considerable experience working with the application of the Company’s technologies and their applications. The Company engages third party experts as required to supplement our internal team. The Company believes that continued development of new and enhanced technologies is essential to our future success. The Company incurred expenses of $3,969,972 and $2,033,726 for the year ended September 30, 2021 and 2020, respectively, on development activities. Advertising Fair Value Measurements and Financial Instruments Fair Value Measurement and Disclosures Level 1 - Quoted prices in active markets for identical assets and liabilities; Level 2 - Inputs other than level one inputs that are either directly or indirectly observable; and. Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of September 30, 2021 and 2020 are based upon the short-term nature of the assets and liabilities. The Company has a money market account which is considered a level 1 asset. The balance as of September 30, 2021 and 2020 was $12,217,714 and $4,252,959, respectively. Derivative Financial Instruments - The Company determined that the conversion features for purposes of bifurcation within its currently outstanding convertible notes payable were immaterial and there was no derivative liability to be recorded as of September 30, 2021 and 2020. Stock Based Compensation Convertible Securities Net Loss per Share As of September 30, 2020, there were options outstanding for the purchase of 4,805,000 common shares (including unearned stock option grants totaling 2,630,000 shares related to performance targets), warrants for the purchase of 20,016,367common shares, and 8,108,356 shares of the Company’s common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 14,659,764 common shares (9,020,264 common shares at the current price of $0.25 per share and 5,639,500 common shares at the current price of $1.00 per share) and are issuable upon conversion of convertible debentures of $7,894,566. All of which could potentially dilute future earnings per share but excluded from the September 30, 2020 calculation of net loss per share because their impact is antidilutive. Comprehensive loss Dividend Policy Use of Estimates Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt --debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging --Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity Based on the Company’s review of accounting standard updates issued since the filing of the 2021 Form 10-K, there have been no other newly issued or newly applicable accounting pronouncements that have had, or are expected to have, a significant impact on the Company’s consolidated financial statements. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

ARTIFICIAL INTELLIGENCE (AI) DE

ARTIFICIAL INTELLIGENCE (AI) DEEP LEARNING PLATFORM	9 Months Ended
	Jun. 30, 2022
ARTIFICIAL INTELLIGENCE (AI) DEEP LEARNING PLATFORM
ARTIFICIAL INTELLIGENCE (AI) DEEP LEARNING PLATFORM	4. Artificial Intelligence (AI) Deep Learning Platform AI Revenue During the nine months ended June 30, 2022, The Company has established a digital wallet and corporate account at Circle in order to receive the Ethereum and then convert it to cash. During 2022, the Company received $2,908,551 of Ethereum which was converted to cash and recorded a reduction in value of $169,884 related to the decline in value of the Ethereum. The accounts receivable-related party was $46,146 as of June 30, 2022. As of June 30, 2022, accrued expenses include $436,378 of expenses, primarily sales and use tax and other expenses. As of June 30, 2022 accrued expenses-related party include $799,353 of unpaid compensation that was due and payable to the CEO for the NFT revenue. This unpaid compensation was paid in July 2022. During 2021, approximately $1.3 million of the selling and transactional costs for the digital assets was paid through the CEO’s personal digital asset account including approximately $1.075 million which was paid to a consultant via the transfer of Ethereum.

FIXED ASSETS

FIXED ASSETS	12 Months Ended
	Sep. 30, 2021
FIXED ASSETS
FIXED ASSETS	4. FIXED ASSETS Property and equipment as of September 30, 2021 and 2020 was comprised of the following: Estimated Useful Lives September 30, 2021 September 30, 2020 Machinery and equipment 2-3 years $ 654,798 $ 355,272 Leasehold improvements 5 years 3,612 3,612 Furniture and fixtures 5 years 26,855 26,855 Less: accumulated depreciation (356,761 ) (257,068 ) $ 328,504 $ 128,671 Total depreciation expense was $99,693 and $69,655 for the year ended September 30, 2021 and 2020, respectively. All equipment is used for general and administrative purposes and accordingly all depreciation is classified in general and administrative expenses.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Jun. 30, 2022
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT	5. PROPERTY AND EQUIPMENT Property and equipment as of June 30, 2022 and September 30, 2021 was comprised of the following: Estimated June 30, September 30, Useful Lives 2022 2021 Machinery and equipment 2-3 years $ 1,498,355 $ 654,798 Leasehold improvements 5 years 3,612 3,612 Furniture and fixtures 5 years 26,855 26,855 Less: accumulated depreciation (575,444 ) (356,761 ) $ 953,378 $ 328,504 Total depreciation expense was $218,683 and $64,980 for the nine months ended June 20, 2022 and 2021, respectively. $207,440 and $10,918 of depreciation was recorded for research and development and selling, general and administrative purposes, respectively, for the nine months ended June 30, 2022. $0 and $64,980 of depreciation was recorded for research and development and selling, general and administrative purposes, respectively, for the nine months ended June 30, 2021.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Sep. 30, 2021
INTANGIBLE ASSETS
INTANGIBLE ASSETS	5. INTANGIBLE ASSETS Intangible assets as of September 30, 2021 and 2020 consisted of the following: Estimated September 30, September 30, Useful Lives 2021 2020 Technology 3 years $ 520,000 $ 520,000 Less: accumulated amortization (520,000 ) (418,886 ) Intangible assets, net $ - $ 101,114 Total amortization expense was $101,114 and $173,332 for the years ended September 30, 2021 and 2020, respectively. Merger with RAAI Lighting, Inc. On April 10, 2018, the Company entered into an Agreement and Plan of Merger with 500 Union Corporation, a Delaware corporation and a wholly owned subsidiary of the Company, and RAAI Lighting, Inc., a Delaware corporation. Pursuant to the Merger Agreement, the Company acquired all the outstanding shares of RAAI’s capital stock through a merger of Merger Sub with and into RAAI (the “Merger”), with RAAI surviving the Merger as a wholly owned subsidiary of the Company. The fair value of the intellectual property associated with the assets acquired was $520,000 estimated by using a discounted cash flow approach based on future economic benefits. In summary, the estimate was based on a projected income approach and related discounted cash flows over five years, with applicable risk factors assigned to assumptions in the forecasted results.

LEASES

LEASES	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
LEASES
LEASES	6. LEASES The Company has entered into operating leases for office and development facilities. These leases have terms which range from two to three years and include options to renew. These operating leases are listed as separate line items on the Company's June 30, 2022 and September 30, 2021 Consolidated Balance Sheets and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as separate line items on the Company's June 30, 2022 and September 30, 2021 Consolidated Balance Sheets. Based on the present value of the lease payments for the remaining lease term of the Company's existing leases, the Company recognized right-of-use assets and lease liabilities for operating leases of approximately $262,242 as of June 30, 2022. Operating lease right-of-use assets and liabilities commencing after October 1, 2018 are recognized at commencement date based on the present value of lease payments over the lease term. During years ended June 30, 2022 and September 30, 2021, the Company amended two leases and recognized the rent payments as an expense in the current period. As of June 30, 2022 and September 30, 2021, total operating lease liabilities for remaining long term lease was approximately $243,076 and $290,000, respectively. In the nine months ended June 30, 2022 and 2021, the Company recognized approximately $130,767 and $102,741, respectively in total lease costs for the leases. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. Information related to the Company's operating right-of-use assets and related lease liabilities as of and for the year ended June 30, 2022 was as follows: Cash paid for ROU operating lease liability $159,112 Weighted-average remaining lease term 20 months Weighted-average discount rate 7% The minimum future lease payments as of June 30, 2022 are as follows: Years Ended June 30, $ 2023 $ 156,253 2024 118,602 Total remaining payments 274,855 Less Imputed Interest (12,629 ) Total lease liability $ 262,226	6. LEASES The Company has entered into operating leases for office and development facilities. These leases have terms which range from two to three years and include options to renew. These operating leases are listed as separate line items on the Company’s September 30, 2021 and 2020 Consolidated Balance Sheets and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as separate line items on the Company’s September 30, 2021 and 2020 Consolidated Balance Sheets. Based on the present value of the lease payments for the remaining lease term of the Company’s existing leases, the Company recognized right-of-use assets and lease liabilities for operating leases of approximately $291,000 as of September 30, 2021. Operating lease right-of-use assets and liabilities commencing after October 1, 2018 are recognized at commencement date based on the present value of lease payments over the lease term. During years ended September 30, 2021 and 2020, the Company had three leases expire and recognized the rent payments as an expense in the current period. As of September 30, 2021 and September 30, 2020, total operating lease liabilities for remaining long term lease was approximately $290,000 and $132,000, respectively. In the year ended September 30, 2021 and 2020, the Company recognized approximately $139,643 and $136,718, respectively in total lease costs for the leases. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. Information related to the Company’s operating right-of-use assets and related lease liabilities as of and for the year ended September 30, 2021 was as follows: Cash paid for ROU operating lease liability $139,643 Weighted-average remaining lease term 28 months Weighted-average discount rate 7% The minimum future lease payments as of September 30, 2021 are as follows: Years Ended September 30, $ 2022 $ 128,987 2023 107,662 2024 73,095 2025 - 2026 - Total Remaining Payments 309,744 Of which Imputed Interest (19,203 ) Total Lease Liability $ 290,541

CONVERTIBLE NOTES PAYABLE AND N

CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE
CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE	7. CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE Convertible notes payable as of June 30, 2022 and September 30, 2021 consisted of the following: Convertible Promissory Notes with Clayton A. Struve The Company owes Clayton A. Struve $1,071,000 under convertible promissory or OID notes. The Company recorded accrued interest of $84,671 and $79,062 as of June 30, 2022 and September 30, 2021, respectively. On May 3, 2022, the Company signed Amendments to the convertible promissory or OID notes, extending the due dates to September 30, 2022. Convertible Redeemable Promissory Notes with Ronald P. Erickson and J3E2A2Z On March 16, 2018, the Company entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833 together with a warrant to purchase up to 1,039,666 shares of common stock of the Company for a period of five years. The initial exercise price of the warrants described above is $0.50 per share, also subject to certain adjustments. The warrants were valued at $110,545. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest. The Company recorded accrued interest of $269,383 and $216,246 as of June 30, 2022 and September 30, 2021, respectively. On April 4, 2022, the Company approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to September 30, 2022. Convertible Debt Offering Beginning in 2019, the Company entered into series of debt offerings with similar and consistent terms. The Company issued Subordinated Convertible Notes and Warrants in a private placement to accredited investors, pursuant to a series of substantially identical Securities Purchase Agreements, Common Stock Warrants, and related documents. The notes are convertible into one share of common stock for each dollar invested in a Convertible Note Payable and automatically convert to common stock after one year. The convertible notes contain terms and conditions which are deemed to be a Beneficial Conversion Feature (BCF). Warrants are issued to purchase common stock with exercise prices of $1.20 and $2.40 per share and the number of warrants are equal to 50% of the convertible note balance. The Company compensates the placement agent with a cash fee and warrants. Through June 30, 2022, the Company has raised approximately $24 million through these offerings, of which $14,209,000 and $5,639,500 were raised in the years ended September 30, 2021 and 2020, respectively. During the year ended September 30, 2021, the Company issued 6,091,960 shares of common stock related to the automatic conversion of Convertible Notes and interest from a private placement to accredited investors in 2020. The Convertible Notes and interested were automatically converted to Common Stock at $1.00 per share on the one year anniversary starting on October 17, 2020. The Convertible Notes issued during the year ended September 30, 2021 are initially convertible into 7,104,500 shares of Common Stock, subject to certain adjustments, and the Warrants are initially exercisable for 3,552,250 shares of Common Stoc. As of June 30, 2022 all convertible notes and accrued interest had been converted to common stock. The fair value of the Warrants issued to debt holders during the year ended September 30, 2021 was $4,439,317 on the date of issuance and was amortized over the one-year term of the Convertible Notes. The fair value of the warrants was recorded as debt discount (with an offset to APIC) and was amortized over the one-year term of the Convertible Notes. In connection with the debt offering during the year ended September 30, 2021, the placement agent for the Convertible Notes and the Warrants received a cash fee of $727,117 and warrants to purchase 492,090 shares of the Company’s common stock, all based on 2-8% of gross proceeds to the Company. The warrants issued for these services had a fair value of $1,667,281 at the date of issuance. The fair value of the warrants was recorded as debt discount (with an offset to APIC) and will be amortized over the one-year term of the Convertible Notes. The $727,117 cash fee was recorded as issuance costs and was amortized over the one-year term of the related Convertible Notes. During the year ended September 30, 2021, the Company recorded a debt discount of $9,769,683 associated with a beneficial conversion feature on the debt, which was accreted to interest expense using the effective interest method over the one-year term of the Convertible Notes. During the nine months ended June 30, 2022, amortization related to the debt offerings of $7,272,911 and $4,184,657 of the beneficial conversion feature, warrants issued to debt holders and placement agent was recognized as interest expense in the consolidated statements of operations. Convertible notes payable as of June 30, 2022 and September 30, 2021 are summarized below: June 30, 2022 September 30, 2021 Convertible note- Clayton A. Struve $ 1,071,000 $ 1,071,000 Convertible note- Ronald P. Erickson and affiliates 1,184,066 1,184,066 2020 Convertible notes - 5,639,500 2021 Convertible notes 14,209,000 14,209,000 Boustead fee refund (originally booked as contra debt) - 50,000 Less conversions of notes (14,209,000 ) (5,639,500 ) Less debt discount - BCF - (4,308,337 ) Less debt discount - warrants - (1,957,590 ) Less debt discount - warrants issued for services - (1,056,984 ) $ 2,255,066 $ 9,191,155 Note Payable-PPP Loans On April 30, 2020, the Company received $226,170 under the Paycheck Protection Program of the U.S. Small Business Administration’s 7(a) Loan Program pursuant to the Coronavirus, Aid, Relief and Economic Security Act (CARES Act), Pub. Law 116-136, 134 Stat. 281 (2020). As of March 31, 2022 and September 30, 2021, the Company recorded interest expense of $4,350 and $3,222 respectively. On April 27, 2022, the Company was notified by the SBA that the Company is required to repay principal of $98,106 and interest of $1,997. The remaining loan and accrued interest balances were forgiven. . On February 1, 2021, the Company received $205,633 under the Paycheck Protection Program of the U.S. Small Business Administration’s 7(a) Loan Program pursuant to the Coronavirus, Aid, Relief and Economic Security Act (CARES Act), Pub. Law 116-136, 134 Stat. 281 (2020). As of June 30, 2022 and September 30, 2021, the Company recorded interest expense of $2,721 and $1,268, respectively. On June 11, 2022, the Company was notified by the SBA that the Company is required to repay principal of $78,843 and interest of $1,057. The remaining loan and accrued interest balances were forgiven. As a result of a portion of these loans being forgiven, the Company recognized a gain on loan forgiveness of approximately $253,000 which is included in other income. EQUITY Authorized Capital Stock The Company was incorporated under the laws of the State of Nevada in 1998. The Company has authorized 205,000,000 shares of capital stock, of which 200,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are “blank check” preferred stock, par value $0.001 per share. As of June 30, 2022, the Company had 43,826,781 shares of common stock and 2,801,719 shares of preferred stock issued and outstanding. As of June 30, 2022, there were options outstanding for the purchase of 20,927,370 common shares (including unearned stock option grants totaling 11,550,745 shares related to performance targets), warrants for the purchase of 21,651,513 common shares, and 8,108,356 shares of our common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 common shares at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,255,066. All of which could potentially dilute future earnings per share but are excluded from the June 30, 2022, calculation of net loss per share because their impact is antidilutive. Annual Shareholder Meeting On October 15, 2021, the Company held its annual shareholder meeting. The Company’s shareholders approved and adopted various motions as detailed in the Company’s Form 8-K that was filed with the SEC on October 19, 2021. Second Amended and Restated Bylaws On October 15, 2021, the shareholders of the Company approving the Second Amended and Restated Bylaws effective October 15, 2021. Certificate of Amendment to Articles of Incorporation On December 6, 2021, the Company received approval from the State of Nevada for a Certificate of Amendment to the Articles of Incorporation related to the increase in the number of authorized common shares. Series C and D Preferred Stock and Warrants On August 5, 2016, the Company closed a Series C Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve, an accredited investor for the purchase of $1,250,000 of preferred stock with a conversion price of $0.70 per share. The preferred stock has a yield of 8% and an ownership blocker of 4.99%. In addition, Mr. Struve received a five-year warrant to acquire 1,785,714 shares of common stock at $0.70 per share. On August 14, 2017, the price of the Series C Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. On June 30, 2022 and September 30, 2021 there are 1,785,715 Series C Preferred shares outstanding. On May 3, 2022, the Company approved the Extension of Warrant Agreement with Clayton Struve, extending the exercise dates to August 4, 2024. As of June 30, 2022 and September 30, 2021, the Company has $750,000 of Series D Preferred Stock outstanding with Clayton A. Struve, an accredited investor. On August 14, 2017, the price of the Series D Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. The Series D Preferred Stock is convertible into shares of common stock at a price of $0.25 per share or by multiplying the number of Series D Preferred Stock shares by the stated value and dividing by the conversion price then in effect, subject to certain diluted events, and has the right to vote the number of shares of common stock the Series D Preferred Stock would be issuable on conversion, subject to a 4.99% blocker. The Preferred Series D has an annual yield of 8% The Series D Preferred Stock is convertible into shares of common stock at a price of $0.25 per share or by multiplying the number of Series D Preferred Stock shares by the stated value and dividing by the conversion price then in effect, subject to certain diluted events, and has the right to vote the number of shares of common stock the Series D Preferred Stock would be issuable on conversion, subject to a 4.99% blocker. The Preferred Series D has an annual yield of 8% if and when dividends are declared. Series F Preferred Stock On August 1, 2018, the Company filed with the State of Nevada a Certificate of Designation establishing the Designations, Preferences, Limitations and Relative Rights of Series F Preferred Stock. The Designation authorized 500 shares of Series F Preferred Stock. The Series F Preferred Stock shall only be issued to the current Board of Directors on the date of the Designation’s filing and is not convertible into common stock. As set forth in the Designation, the Series F Preferred Stock has no rights to dividends or liquidation preference and carries rights to vote 100,000 shares of common stock per share of Series F upon a Trigger Event, as defined in the Designation. A Trigger Event includes certain unsolicited bids, tender offers, proxy contests, and significant share purchases, all as described in the Designation. Unless and until a Trigger Event, the Series F shall have no right to vote. The Series F Preferred Stock shall remain issued and outstanding until the date which is 731 days after the issuance of Series F Preferred Stock (“Explosion Date”), unless a Trigger Event occurs, in which case the Explosion Date shall be extended by 183 days. As of June 30, 2022 and September 30, 2021, there are no Series F shares outstanding. Securities Subject to Price Adjustments If in the future, if the Company sells its common stock at a price below $0.25 per share, the conversion price of 8,108,356 outstanding shares of Series C and D Preferred Stock would adjust below $0.25 per share pursuant to the documents governing such instruments. In addition, the conversion price of Convertible Notes Payable in the principal amount of $2,255,066, that convert into 9,020,264 shares of our common stock at $0.25 per share and the exercise price of certain outstanding warrants to purchase 10,284,381 shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments. Warrants totaling 4,487,207 would adjust below $1.20 per share and warrants totaling 3,954,625 would adjust below $2.40 per share, in each case pursuant to the documents governing such instruments. Common Stock All of the offerings and sales described below were deemed to be exempt under Rule 506 of Regulation D and/or Section 4(a)(2) of the Securities Act. No advertising or general solicitation was employed in offering the securities, the offerings and sales were made to a limited number of persons, all of whom were accredited investors and transfer was restricted by the company in accordance with the requirements of Regulation D and the Securities Act. All issuances to accredited and non-accredited investors were structured to comply with the requirements of the safe harbor afforded by Rule 506 of Regulation D, including limiting the number of non-accredited investors to no more than 35 investors who have sufficient knowledge and experience in financial and business matters to make them capable of evaluating the merits and risks of an investment in our securities. Nine Months Ended June 30, 2022 During the nine months ended June 30, 2022, the Company issued 863,986 shares of common stock related to warrant exercises and received $793,986. During the nine months ended June 30, 2022, the Company issued 8,750 shares related to the exercise of stock option grants and received $13,688. The Company issued 7,672,860 shares of common stock related to the automatic conversion of Convertible Notes and interest from a private placement to accredited investors in 2021. The Convertible Notes and interested were automatically converted to Common Stock at $2.00 per share on the one year anniversary in March 2022. On January 5, 2022, the Company issued 30,000 shares each to three directors shares at an exercise price of $1.70 per share. Warrants to Purchase Common Stock Nine Months Ended June 30, 2022 On January 5, 2022, the Company issued 20,000 warrants to purchase common stock each to three directors shares at $1.70 per share. The warrants expire on January 5, 2027. During the nine months ended June 30, 2022, warrants to purchase 108,756 shares of common stock at $1.00 per share expired. Extension of Warrant Agreement with Clayton A. Struve On May 3, 2022, the Company approved the Extension of Warrant Agreement with Clayton Struve, extending the exercise dates as follows: Warrant No./Class Issue Date No. Warrant Shares Exercise Price Original Expiration Date Amended Expiration Date Clayton A. Struve Warrant 08-14-2017 1,440,000 $ 0.25 08-13-2023 08-13-2024 Clayton A. Struve Warrant 12-12-2017 1,200,000 $ 0.25 12-11-2023 12-11-2024 Clayton A. Struve Warrant 08-04-2016 1,785,715 $ 0.25 08-04-2023 08-04-2024 Clayton A. Struve Warrant 02-28-2018 1,344,000 $ 0.25 02-28-2023 02-28-2024 The Company recorded interest expense of $244,260 during the nine months ended June 30, 2022 related to the extension of the warrants. June 30, 2022 Weighted Average Exercise Shares Price Outstanding at beginning of period 22,564,255 $ 0.998 Issued 60,000 - Exercised (863,986 ) (0.919 ) Forfeited - - Expired (108,756 ) (1.000 ) Outstanding at end of period 21,651,513 $ 1.003 Exerciseable at end of period 21,651,513 The following table summarizes information about warrants outstanding and exercisable as of June 30, 2022: June 30, 2022 Weighted Weighted Weighted Average Average Average Number of Remaining Exercise Shares Exercise Warrants Life ( In Years) Price Exerciseable Price 10,729,381 4.79 $ 0.250 10,729,381 $ 0.250 6,547,207 2.59 1.20-1.85 6,547,207 1.20-1.85 4,364,925 3.77 2.00-2.40 4,364,925 2.00-2.40 10,000 1.00 4.080 10,000 4.080 21,651,513 3.43 $ 1.003 21,651,513 $ 1.003 There were vested warrants of 21,651,513 with an aggregate intrinsic value of $31,557,563.	7. CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE Convertible notes payable as of September 30, 2021 and 2020 consisted of the following: Convertible Promissory Notes with Clayton A. Struve The Company owes Clayton A. Struve $1,071,000 under convertible promissory or OID notes. The Company recorded accrued interest of $79,062 and $71,562 as of September 30, 2021 and 2020, respectively. On December 23, 2020, the Company signed Amendments to the convertible promissory or OID notes, extending the due dates to March 31, 2021. On November 8, 2021, the Company signed Amendments to the convertible promissory or OID notes, extending the due dates to March 31, 2022. Mr. Struve also invested $1,000,000 in the May 2019 Convertible Debt Offering and such note was converted to common stock in May 2020. Convertible Redeemable Promissory Notes with Ronald P. Erickson and J3E2A2Z On March 16, 2018, the Company entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833 together with a warrant to purchase up to 1,039,666 shares of common stock of the Company for a period of five years. The initial exercise price of the warrants described above is $0.50 per share, also subject to certain adjustments. The warrants were valued at $110,545. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest. The Company recorded accrued interest of $216,246 and $145,202 as of September 30, 2021 and 2020, respectively. On September 30, 2021, the Company approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to March 31, 2022. Convertible Debt Offering Beginning in 2019, the Company entered into series of debt offerings with similar and consistent terms. The Company issued Subordinated Convertible Notes and Warrants in a private placement to accredited investors, pursuant to a series of substantially identical Securities Purchase Agreements, Common Stock Warrants, and related documents. The notes are convertible into one share of common stock for each dollar invested in a Convertible Note Payable and automatically convert to common stock after one year. The convertible notes contain terms and conditions which are deemed to be a Beneficial Conversion Feature (BCF). Warrants are issued to purchase common stock with exercise prices of $1.20 and $2.40 per share and the number of warrants are equal to 50% of the convertible note balance. The Company compensates the placement agent with a cash fee and warrants. Through December 31, 2021, the Company has raised approximately $24 million through these offerings, of which $14,209,000 and $5,639,500 were raised in the years ended September 30, 2021 and 2020, respectively. The Convertible Notes issued during the year ended September 30, 2021 are initially convertible into 7,104,500 shares of Common Stock, subject to certain adjustments, and the Warrants are initially exercisable for 3,552,250 shares of Common Stock. The fair value of the Warrants issued to debt holders during the year ended September 30, 2021 was $4,439,317 on the date of issuance and will be amortized over the one-year term of the Convertible Notes. The fair value of the warrants was recorded as debt discount (with an offset to APIC) and will be amortized over the one-year term of the Convertible Notes. In connection with the debt offering during the year ended June 30, 2021, the placement agent for the Convertible Notes and the Warrants received a cash fee of $727,117 and warrants to purchase 492,090 shares of the Company’s common stock, all based on 2-8% of gross proceeds to the Company. The warrants issued for these services had a fair value of $1,667,281 at the date of issuance. The fair value of the warrants was recorded as debt discount (with an offset to APIC) and will be amortized over the one-year term of the Convertible Notes. The $727,117 cash fee was recorded as issuance costs and will be amortized over the one-year term of the related Convertible Notes. During the years ended September 30, 2021 and 2020, the Company recorded a debt discount of $9,769,683 and $3,766,074 associated with a beneficial conversion feature on the debt, which is being accreted using the effective interest method over the one-year term of the Convertible Notes. During the year ended September 30, 2021, the Company issued 6,091,960 shares of common stock related to the automatic conversion of Convertible Notes and interest from a private placement to accredited investors in 2020. The Convertible Notes and interested were automatically converted to Common Stock at $1.00 per share on the one year anniversary starting on October 17, 2020. During the year ended September 30, 2021 and 2020, amortization related to the debt offerings of $13,256,250 and $5,662,690 of the beneficial conversion feature, warrants issued to debt holders and placement agent was recognized as interest expense in the consolidated statements of operations. Convertible notes payable as of September 30, 2021 and 2020 are summarized below: September 30, 2021 September 30, 2020 Convertible note- Clayton A. Struve $ 1,071,000 $ 1,071,000 Convertible note- Ronald P. Erickson and affiliates 1,184,066 1,184,066 2019 Convertible notes 4,242,490 4,242,490 2020 Convertible notes 5,639,500 5,639,500 Q2 2021 Convertible notes 14,209,000 - Boustead fee refund (originally booked as contra debt) 50,000 50,000 Less conversions of notes (9,881,990 ) (4,242,490 ) Less debt discount - BCF (4,308,337 ) (2,127,894 ) Less debt discount - warrants (1,957,590 ) (1,025,512 ) Less debt discount - warrants issued for services (1,056,984 ) (823,582 ) $ 9,191,155 $ 3,967,578 Note Payable-PPP Loans On April 30, 2020, the Company received $226,170 under the Paycheck Protection Program of the U.S. Small Business Administration’s 7(a) Loan Program pursuant to the Coronavirus, Aid, Relief and Economic Security Act (CARES Act), Pub. Law 116-136, 134 Stat. 281 (2020). As of September 30, 2021 and 2020, the Company recorded interest expense of $3,222 and $960, respectively. The Company utilized the funds in accordance with the legal requirements and expects this loan to be forgiven. Until the loan is legally forgiven, the loan balance will outstanding. The Company filed the application for the loan forgiveness during the three months ended December 31, 2021 and the Company is expecting approval by the SBA. On February 1, 2021, the Company received $205,633 under the Paycheck Protection Program of the U.S. Small Business Administration’s 7(a) Loan Program pursuant to the Coronavirus, Aid, Relief and Economic Security Act (CARES Act), Pub. Law 116-136, 134 Stat. 281 (2020). As of September 30, 2021, the Company recorded interest expense of $1,268. The Company utilized the funds in accordance with the legal requirements and expects this loan to be forgiven. Until the loan is legally forgiven, the loan balance will be outstanding. The Company filed the application for the loan forgiveness during the three months ended December 31, 2021 and the Company is expecting approval by the SBA.

SIMPLE AGREEMENTS FOR FUTURE EQ

SIMPLE AGREEMENTS FOR FUTURE EQUITY	12 Months Ended
	Sep. 30, 2021
CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE
SIMPLE AGREEMENTS FOR FUTURE EQUITY	8. SIMPLE AGREEMENTS FOR FUTURE EQUITY In July 2020, Particle entered into Simple Agreements for Future Equity (“SAFE”) with twenty two accredited investors pursuant to which Particle received $785,000 in cash in exchange for the providing the investor the right to receive shares of the Particle stock. The Company expects to issue 981,250 shares of the Particle stock that was initially valued at $0.80 per share. The Company paid $47,100 in broker fees which were expensed as business development expenses. In October 2020, Particle entered into Simple Agreements for Future Equity (“SAFE”) with two accredited investors pursuant to which Particle received $55,000 in cash in exchange for the providing the investor the right to receive shares of the Particle stock. The Company expects to issue 68,750 shares of the Particle stock that was initially valued at $0.80 per share. The Company paid $4,125 in broker fees which were expensed as business development expenses. During the three months ended March 31, 2021, Particle entered into Simple Agreements for Future Equity (“SAFE”) with five accredited investors pursuant to which Particle received $340,000 in cash in exchange for the providing the investor the right to receive shares of the Particle stock. The Company expects to issue 68,750 shares of the Particle stock that was initially valued at $0.80 per share. The Company paid $23,660 in broker fees which were expensed as business development expenses. Through August 9, 2021, $1,125,000 has been raised through the sale of SAFE instruments. On this date, certain investors elected to convert their SAFE instruments balance and accrued interest into Know Labs common stock. The Company issued 480,600 shares of common stock at an average price of $2.00 per share or $961,200 related to the conversion into the Company’s common shares. The exercise price was below the fair market value of Know Labs stock, as such the Company recorded a beneficial conversion feature of $72,090. The Company also issued five year warrants to these investors for 240,000 shares of the Company’s common stock. The warrants are exercisable at $2.40 per share. The warrants were valued at $1.641 per share or $394,332 and were expensed during the current year The Company repaid $253,800 to investors that elected to redeem their SAFE instruments for cash. The Company recorded interest expense of $90,000 and paid $54,108 to Boustead Securities LLC in fees during the year ended September 30, 2021 related to this transaction. The Company also issued a five year warrant to Boustead Securities LLC for 43,254 shares of the Company’s common stock. The warrant is exercisable at $2.40 per share and was valued at $1.641 per share or $70,980.

EQUITY

EQUITY	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
EQUITY
EQUITY	8. EQUITY  Authorized Capital Stock The Company was incorporated under the laws of the State of Nevada in 1998. The Company has authorized 205,000,000 shares of capital stock, of which 200,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share. At the annual shareholder meeting held on October 15, 2021, our authorized shares of common stock was increased to 200,000,000 shares of voting common stock, par value $0.001 per share.  As of March 31, 2022, there were options outstanding for the purchase of 17,878,245 common shares (including unearned stock option grants totaling 11,550,745 shares related to performance targets), warrants for the purchase of 21,714,023 common shares, and 8,108,356 shares of our common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 common shares at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,255,066. All of which could potentially dilute future earnings per share but are excluded from the March 31, 2022, calculation of net loss per share because their impact is antidilutive.  Annual Shareholder Meeting  On October 15, 2021, the Company held its annual shareholder meeting. The Company’s shareholders approved and adopted various motions as detailed in the Company’s Form 8-K that was filed with the SEC on October 19, 2021. Second Amended and Restated Bylaws On October 15, 2021, the shareholders of the Company approving the Second Amended and Restated Bylaws effective October 15, 2021.  Certificate of Amendment to Articles of Incorporation On December 6, 2021, the Company received approval from the State of Nevada for a Certificate of Amendment to the Articles of Incorporation related to the increase in the number of authorized common shares. Series C and D Preferred Stock and Warrants On August 5, 2016, the Company closed a Series C Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve, an accredited investor for the purchase of $1,250,000 of preferred stock with a conversion price of $0.70 per share. The preferred stock has a yield of 8% and an ownership blocker of 4.99%. In addition, Mr. Struve received a five-year warrant to acquire 1,785,714 shares of common stock at $0.70 per share. On August 14, 2017, the price of the Series C Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. On March 31, 2022 and September 30, 2021 there are 1,785,715 Series C Preferred shares outstanding. On May 3, 2022, the Company approved the Extension of Warrant Agreement with Clayton Struve, extending the exercise dates to August 4, 2024.  As of March 31, 2022 and September 30, 2021, the Company has $750,000 of Series D Preferred Stock outstanding with Clayton A. Struve, an accredited investor. On August 14, 2017, the price of the Series D Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. The Series D Preferred Stock is convertible into shares of common stock at a price of $0.25 per share or by multiplying the number of Series D Preferred Stock shares by the stated value and dividing by the conversion price then in effect, subject to certain diluted events, and has the right to vote the number of shares of common stock the Series D Preferred Stock would be issuable on conversion, subject to a 4.99% blocker. The Preferred Series D has an annual yield of 8% The Series D Preferred Stock is convertible into shares of common stock at a price of $0.25 per share or by multiplying the number of Series D Preferred Stock shares by the stated value and dividing by the conversion price then in effect, subject to certain diluted events, and has the right to vote the number of shares of common stock the Series D Preferred Stock would be issuable on conversion, subject to a 4.99% blocker. The Preferred Series D has an annual yield of 8% if and when dividends are declared. Series F Preferred Stock On August 1, 2018, the Company filed with the State of Nevada a Certificate of Designation establishing the Designations, Preferences, Limitations and Relative Rights of Series F Preferred Stock. The Designation authorized 500 shares of Series F Preferred Stock. The Series F Preferred Stock shall only be issued to the current Board of Directors on the date of the Designation’s filing and is not convertible into common stock. As set forth in the Designation, the Series F Preferred Stock has no rights to dividends or liquidation preference and carries rights to vote 100,000 shares of common stock per share of Series F upon a Trigger Event, as defined in the Designation. A Trigger Event includes certain unsolicited bids, tender offers, proxy contests, and significant share purchases, all as described in the Designation. Unless and until a Trigger Event, the Series F shall have no right to vote. The Series F Preferred Stock shall remain issued and outstanding until the date which is 731 days after the issuance of Series F Preferred Stock (“Explosion Date”), unless a Trigger Event occurs, in which case the Explosion Date shall be extended by 183 days. As of March 31, 2022 and September 30, 2021, there are no Series F shares outstanding.  Securities Subject to Price Adjustments  In the future, if the Company’s sells its common stock at a price below $0.25 per share, the exercise price of 8,108,356 outstanding shares of Series C and D Preferred Stock that adjust below $0.25 per share pursuant to the documents governing such instruments. In addition, the conversion price of Convertible Notes Payable of $2,255,066 or 9,020,264 common shares at $0.25 per share and the exercise price of additional outstanding warrants to purchase 10,334,381 shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments. Warrants totaling 4,487,207 would adjust below $1.20 per share pursuant to the documents governing such instruments. Warrants totaling 3,954,625 would adjust below $2.40 per share pursuant to the documents governing such instruments. Common Stock All of the offerings and sales described below were deemed to be exempt under Rule 506 of Regulation D and/or Section 4(a)(2) of the Securities Act. No advertising or general solicitation was employed in offering the securities, the offerings and sales were made to a limited number of persons, all of whom were accredited investors and transfer was restricted by the company in accordance with the requirements of Regulation D and the Securities Act. All issuances to accredited and non-accredited investors were structured to comply with the requirements of the safe harbor afforded by Rule 506 of Regulation D, including limiting the number of non-accredited investors to no more than 35 investors who have sufficient knowledge and experience in financial and business matters to make them capable of evaluating the merits and risks of an investment in our securities. Six Months Ended March 31, 2022 The Company issued 801,486 shares of common stock related to warrant exercises and received $766,486. The Company issued 6,875 shares related to the exercise of stock option grants and received $11,344. The Company issued 7,672,860 shares of common stock related to the automatic conversion of Convertible Notes and interest from a private placement to accredited investors in 2021. The Convertible Notes and interested were automatically converted to Common Stock at $2.00 per share on the one year anniversary in March 2022. On January 5, 2022, the Company issued 30,000 shares each to three directors shares at an exercise price of $1.70 per share.  On January 5, 2022, the Company issued 20,000 warrants to purchase common stock each to three directors shares at $1.70 per share. The warrants expire on January 5, 2027.  Warrants to Purchase Common Stock Six Months Ended March 31, 2022 On January 5, 2022, the Company issued 20,000 warrants to purchase common stock each to three directors shares at $1.70 per share. The warrants expire on January 5, 2027.  During the six months ended March 31, 2022, the Company issued 801,486 shares of common stock related to warrant exercises and received $766,486. During the six months ended March 31, 2022, warrants to purchase 108,756 shares of common stock at $1.00 per share expired.    March 31, 2022      Weighted      Average      Exercise   Shares  Price Outstanding at beginning of period  22,564,255  $0.998 Issued  60,000   - Exercised  (801,486)  (0.956)Forfeited  -   - Expired  (108,756)  (1.000)Outstanding at end of period  21,714,013  $1.001 Exerciseable at end of period  21,714,013      The following table summarizes information about warrants outstanding and exercisable as of March 31, 2022:    March 31, 2022    Weighted  Weighted     Weighted    Average  Average     Average Number of  Remaining   Exercise  Shares   Exercise Warrants  Life ( In Years)  Price  Exercisable  Price  10,779,381   1.02  $0.250   10,779,381  $0.250                     6,559,707   2.84   1.20-1.85    6,559,707   1.20-1.85   4,364,925   4.00   2.00-2.40    4,364,925   2.00-2.40   10,000   1.25   4.080   10,000   4.080  21,714,013   3.17  $1.001   21,714,013  $1.001   There were vested warrants of 21,714,013 with an aggregate intrinsic value of $19,956,371.	9. EQUITY Authorized Capital Stock The Company has authorized 105,000,000 shares of capital stock, of which 100,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares of preferred stock, par value $0.001 per share. At the annual shareholder meeting held on October 15, 2021, our authorized shares of common stock was increased to 200,000,000 shares of voting common stock, par value $0.001 per share. We have authorized 5,000,000 are shares of preferred stock, par value $0.001 per share. As of September 30, 2021, we had 35,166,551 shares of common stock issued and outstanding, held by 163 stockholders of record. The number of stockholders, including beneficial owners holding shares through nominee names, is approximately 3,600. Each share of common stock entitles its holder to one vote on each matter submitted to the stockholders for a vote, and no cumulative voting for directors is permitted. Stockholders do not have any preemptive rights to acquire additional securities issued by the Company. As of September 30, 2021, there were options outstanding for the purchase of 15,315,120 common shares (including unearned stock option grants totaling 11,775,745 shares related to performance targets), warrants for the purchase of 22,564,255 common shares, and 8,108,356 shares of the Company’s common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 16,124,764 common shares (9,020,264 common shares at the current price of $0.25 per share and 7,104,500 common shares at the current price of $2.00 per share) reserved and are issuable upon conversion of convertible debentures of $16,464,066. All of which could potentially dilute future earnings per share but are excluded from the September 30, 2021, calculation of net loss per share because their impact is antidilutive. Series C and D Preferred Stock and Warrants On August 5, 2016, the Company closed a Series C Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve, an accredited investor for the purchase of $1,250,000 of preferred stock with a conversion price of $0.70 per share. The preferred stock has a yield of 8% and an ownership blocker of 4.99%. In addition, Mr. Struve received a five-year warrant to acquire 1,785,714 shares of common stock at $0.70 per share. On August 14, 2017, the price of the Series C Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. On September 30, 2021 and 2020 there are 1,785,715 Series C Preferred shares outstanding. On January 5, 2021, the Company extended the warrant expiration date to August 4, 2023. As of September 30, 2021 and 2020, the Company has $750,000 of Series D Preferred Stock outstanding with Clayton A. Struve, an accredited investor. On August 14, 2017, the price of the Series D Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. The Series D Preferred Stock is convertible into shares of common stock at a price of $0.25 per share or by multiplying the number of Series D Preferred Stock shares by the stated value and dividing by the conversion price then in effect, subject to certain diluted events, and has the right to vote the number of shares of common stock the Series D Preferred Stock would be issuable on conversion, subject to a 4.99% blocker. The Preferred Series D has an annual yield of 8% The Series D Preferred Stock is convertible into shares of common stock at a price of $0.25 per share or by multiplying the number of Series D Preferred Stock shares by the stated value and dividing by the conversion price then in effect, subject to certain diluted events, and has the right to vote the number of shares of common stock the Series D Preferred Stock would be issuable on conversion, subject to a 4.99% blocker. The Preferred Series D has an annual yield of 8% if and when dividends are declared. Series F Preferred Stock On August 1, 2018, the Company filed with the State of Nevada a Certificate of Designation establishing the Designations, Preferences, Limitations and Relative Rights of Series F Preferred Stock. The Designation authorized 500 shares of Series F Preferred Stock. The Series F Preferred Stock shall only be issued to the current Board of Directors on the date of the Designation’s filing and is not convertible into common stock. As set forth in the Designation, the Series F Preferred Stock has no rights to dividends or liquidation preference and carries rights to vote 100,000 shares of common stock per share of Series F upon a Trigger Event, as defined in the Designation. A Trigger Event includes certain unsolicited bids, tender offers, proxy contests, and significant share purchases, all as described in the Designation. Unless and until a Trigger Event, the Series F shall have no right to vote. The Series F Preferred Stock shall remainissued and outstanding until the date which is 731 days after the issuance of Series F Preferred Stock (“Explosion Date”), unless a Trigger Event occurs, in which case the Explosion Date shall be extended by 183 days. As of September 30, 2021 and 2020, there are no Series F shares outstanding. Securities Subject to Price Adjustments In the future, if the Company sells its common stock at a price below $0.25 per share, the exercise price of 8,108,356 outstanding shares of Series C and D Preferred Stock that adjust below $0.25 per share pursuant to the documents governing such instruments. In addition, the conversion price of Convertible Notes Payable of $16,464,066 or 16,124,764 common shares (9,020,264 common shares at $0.25 per share and 7,104,500 at $2.00) and the exercise price of additional outstanding warrants to purchase 10,384,381 shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments. Warrants totaling 4,487,207 would adjust below $1.20 per share pursuant to the documents governing such instruments. Warrants totaling 3,954,625 would adjust below $2.40 per share pursuant to the documents governing such instruments. Common Stock All of the offerings and sales described below were deemed to be exempt under Rule 506 of Regulation D and/or Section 4(a)(2) of the Securities Act. No advertising or general solicitation was employed in offering the securities, the offerings and sales were made to a limited number of persons, all of whom were accredited investors and transfer was restricted by the company in accordance with the requirements of Regulation D and the Securities Act. All issuances to accredited and non-accredited investors were structured to comply with the requirements of the safe harbor afforded by Rule 506 of Regulation D, including limiting the number of non-accredited investors to no more than 35 investors who have sufficient knowledge and experience in financial and business matters to make them capable of evaluating the merits and risks of an investment in our securities. Year Ended September 30, 2021 The Company issued 6,091,960 shares of common stock related to the automatic conversion of Convertible Notes and interest from a private placement to accredited investors in 2020. The Convertible Notes and interested were automatically converted to Common Stock at $1.00 per share on the one year anniversary starting on October 17, 2020. The Company issued 3,676,542 shares of common stock at an average price of 0.582 per share related to the exercise of warrants. The Company issued 97,000 shares related to services. The shares were valued at the fair market value of $202,820. The Company issued 16,875 shares related to the exercise of stock option grants at $1.38 per share. The Company issued 480,600 shares of common stock at an average price of $2.00 per share or $961,200 related to the conversion of Particle Simple Agreements for Future Equity into the Company’s common shares. Year Ended September 30, 2020 On November 9, 2019, a former employee exercised stock option grants on a cashless basis. The former employee received 73,191 shares of common stock for vested stock option grants. The stock option grant had an exercise price of $0.25 per share. During the year ended September 30, 2020, the Company issued 550,000 shares of restricted common stock for services. The shares were issued were valued at $1.90 per share, the market price of our common stock, or $1,045,000. During the year ended September 30, 2020, the Company issued 4,581,917 shares of common stock related to the automatic conversion of Convertible Notes and interest from a private placement to accredited investors in 2019. The Convertible Notes and interested were automatically converted to Common Stock at $1.00 per share on the one year anniversary starting on February 15, 2020. During the year ended September 30, 2020, the Company issued 733,588 shares of common stock at $0.889 per share related to the exercise of warrants. On July 1, 2020, the Company entered into a Settlement Agreement and General Mutual Release with a shareholder of the Company. On July 6, 2020, the shareholder paid $125,000 us and we issued 500,000 shares of common stock. We accrued for the loss on debt settlement of $825,000 as of June 30, 2020 which represents the difference between the fair market value of the stock and $125,000 paid by the shareholder. Warrants to Purchase Common Stock Year Ended September 30, 2021 The Company issued warrants to Ronald P. Erickson for 2,000,000 shares of common stock. The five year warrant is immediately vested and exercisable on a cash or cashless basis at $1.53 per share and was valued using a Black-Scholes model at $1,811,691. During the year ended September 30, 2021, the Company issued warrants to five directors and service providers for 269,510 shares of common stock. The five year warrant is convertible at $1.918 per share and was valued using a Black-Scholes model at $735,745. The Convertible Notes issued during the year ended September 30, 2021 are initially convertible into 7,104,500 shares of Common Stock, subject to certain adjustments, and the Warrants are initially exercisable for 3,552,250 shares of Common Stock. The Company issued 3,676,542 shares of common stock at an average price of $0.582 per share related to the exercise of warrants. Warrants to exercise 384,359 shares of common stock were forfeited at an average of $1.155 per share. The Company also issued a five year warrant to Boustead Securities LLC for 43,254 shares of the Company’s common stock related to the conversion of Particle Simple Agreements for Future Equity into the Company’s common shares. The warrant is exercisable at $2.40 per share. The warrant was valued at $1.641 per share or $70,980. Year Ended September 30, 2020 The following warrant transactions occurred during the year ended September 30, 2020: During the year ended September 30, 2020, the Company issued 733,588 shares of common stock at $0.952 per share and cancelled warrants to purchase 507,560 shares of common stock at $1.120 per share to related to the exercise of warrants. During the year ended September 30, 2020, the Company issued 75,000 shares of common stock at $1.95 per share. The warrant was valued at $1.770 per share. Convertible Debt Offering Warrants The Warrants issued for the 2020 convertible Debt Offering were granted on a 1:0.5 basis (one-half Warrant for each full share of Common Stock into which the Convertible Notes are convertible). The Warrants have a five-year term and an exercise price equal to 120% of the per share conversion price of the Qualified Financing or other mandatory conversion. Warrants issued in connection with 2020 convertible debt offering are initially exercisable for 2,819,750 shares of Common Stock at an exercise price of $1.20 per share of Common Stock, also subject to certain adjustments. In connection with the 2020 convertible debt offering, the placement agent for the Convertible Notes and the Warrants received warrants to 615,675 shares of the Company’s common stock, all based on 8% of gross proceeds to the Company. A summary of the warrants outstanding as of September 30, 2021 were as follows: September 30, 2021 Weighted Average Exercise Shares Price Outstanding at beginning of period 20,016,367 $ 0.556 Issued 6,608,789 2.117 Exercised (3,676,542 ) (0.582 ) Forfeited (384,359 ) (1.155 ) Expired - - Outstanding at end of period 22,564,255 $ 0.998 Exerciseable at end of period 22,564,255 The following table summarizes information about warrants outstanding and exercisable as of September 30, 2021: September 30, 2021 Weighted Weighted Weighted Average Average Average Number of Remaining Exercise Shares Exercise Warrants Life ( In Years) Price Exerciseable Price 10,829,381 1.24 $ 0.250 10,829,381 $ 0.250 847,742 0.12 1.000 847,742 1.000 6,512,207 3.32 1.20-1.85 6,512,207 1.20-1.85 4,364,925 4.50 2.00-2.40 4,364,925 2.00-2.40 10,000 1.75 4.080 10,000 4.080 22,564,255 3.49 $ 0.998 22,564,255 $ 0.998 The significant weighted average assumptions relating to the valuation of the Company’s warrants for the year ended September 30, 2021 were as follows: Dividend yield 0 % Expected life 3-5 years Expected volatility 140 % Risk free interest rate 0.37 % There were vested and in the money warrants of 22,554,255 with an aggregate intrinsic value of $34,314,540.

STOCK INCENTIVE PLAN

STOCK INCENTIVE PLAN	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
EQUITY
STOCK INCENTIVE PLAN	9. STOCK INCENTIVE PLANS 2021 Equity Incentive Plan The Company initially had 20,000,000 shares of its common stock authorized as the maximum number of shares of the Company’s common stock that may be delivered to participants under the 2021 Plan, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. This number was increased to 22,000,000 shares of common stock as of January 1, 2022 as a result of the automatic share reserve increase. Shares subject to an award under the 2021 Plan for which the award is canceled, forfeited or expires again become available for grants under the 2021 Plan. Shares subject to an award that is settled in cash will not again be made available for grants under the 2021 Plan. As of the date of this report on Form 10-Q, 15,722,750 shares of our common stock remain available for issuance under the 2021 Plan. The 2021 Plan also authorizes for issuance the sum of (A) any shares of our common stock that, as of the date of stockholder approval of the 2021 Plan, have been reserved but not issued pursuant to any awards granted under our 2011 Stock Incentive Plan, as amended, or the 2011 Plan, and (B) any shares of our common stock subject to stock options or similar awards granted under the 2011 Plan that, after the date of stockholder approval of the 2021 Plan, expire or otherwise terminate without having been exercised in full and shares of our common stock issued pursuant to awards granted under the 2011 Plan that are forfeited to or repurchased by us, with the maximum number of shares of our common stock to be added to the 2021 Plan pursuant to clause (ii) equal to 14,650,120. Nine Months Ended June 30, 2022 On December 16, 2021, the Company issued a stock option grant to Ronald P. Erickson for 1,000,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. On December 16, 2021, the Company issued a stock option grant to Phillip A. Bosua for 1,300,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. On May 20, 2022, the Company issued a stock option grant to Peter Conley for 1,000,000 shares at an exercise price of $1.48 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years after two quarters. During the nine months ended June 30, 2022, the Compensation committee also issued stock option grants to eighteen employees and consultants for 3,146,000 shares at an average exercise price of $1.699 per share. The stock option grants expire in five years. The stock option grant primarily vest quarterly over four years. During the nine months ended June 30, 2022, the Company issued 8,750 shares related to the exercise of stock option grants and received $13,688. During the nine months ended June 30, 2022, five employees and consultants forfeited stock option grants for 825,000 shares at an average $1.838 per share. There are currently 20,927,370 (including unearned stock option grants totaling 11,550,745 shares related to performance milestones) options to purchase common stock at an average exercise price of $1.628 per share outstanding as of June 30, 2022 under the 2021 Stock Incentive Plan. The Company recorded $1,555,875 and $570,514 of compensation expense, net of related tax effects, relative to stock options for the nine months ended June 30, 2022 and 2021, respectively in accordance with ASC 718. As of June 30, 2022, there is $7,065,596, net of forfeitures, of total unrecognized costs related to employee granted stock options that are not vested. These costs are expected to be recognized over a period of approximately 4.15 years. Stock option activity for the nine months ended June 30, 2022 and the years ended September 30, 2021 and 2020 was as follows: Weighted Average Options Exercise Price Proceed $ Outstanding as of October 1, 2019 4,532,668 $ 2.025 $ 9,180,369 Granted 3,085,000 1.142 3,522,400 Exercised (73,191 ) (0.250 ) (18,298 ) Forfeitures (2,739,477 ) (2.593 ) (7,103,921 ) Outstanding as of September 30, 2020 4,805,000 1.161 5,580,550 Granted 10,650,745 1.766 18,807,990 Exercised (20,625 ) (1.359 ) (28,031 ) Forfeitures (120,000 ) (3.300 ) (396,000 ) Outstanding as of September 30, 2021 15,315,120 1.565 23,964,509 Granted 6,446,000 1.805 11,632,130 Exercised (8,750 ) (1.564 ) (13,688 ) Forfeitures (825,000 ) (1.838 ) (1,516,150 ) Outstanding as of June 30, 2022 20,927,370 $ 1.628 $ 34,066,802 The following table summarizes information about stock options outstanding and exercisable as of June 30, 2022: Weighted Weighted Weighted Average Average Average Range of Number Remaining Life Exercise Price Number Exercise Price Exercise Prices Outstanding In Years Outstanding Exerciseable Exerciseable $ 0.25 230,000 0.96 $ 0.250 201,250 $ 0.250 1.10-1.25 2,930,625 2.35 1.101 548,307 1.105 1.28-1.67 12,330,745 2.46 1.503 1,175,521 1.303 1.79-3.67 5,436,000 4.25 1.195 665,063 1.917 20,927,370 4.15 1.628 2,590,141 $ 1.241 There are stock option grants of 20,927,370 shares as of June 30, 2022 with an aggregate intrinsic value of $22,540,075. As of September 30, 2021, the 2020 Particle Stock Incentive Plan, was terminated and all stock option grants were cancelled by the participants. The Company recorded $197,553 and $833,771 of compensation expense, net of related tax effects, relative to Particle stock options for the years ended September 30, 2021 and 2020 and in accordance with ASC 718.	10. STOCK INCENTIVE PLANS Know Labs, Inc. Stock Incentive Plan On January 23, 2019, the Board approved an amendment to its 2011 Stock Incentive Plan increasing the number of shares of common stock reserved under the Incentive Plan from 2,200,000 to 2,500,000 to common shares. On May 22, 2019, the Compensation Committee approved an amendment to its 2011 Stock Incentive Plan increasing the number of shares of common stock reserved under the Incentive Plan from 2,500,000 to 3,000,000 to common shares. On November 23, 2020, the Board of Directors increased the size of the stock available under the Stock Option Plan by 9,750,000 shares. This increase is based on an industry peer group study. On October 15, 2021, at the annual shareholder meeting held on October 15, 2021, the 2021 Equity Incentive Plan was adopted and approved, increasing size of the stock available under the Stock Option Plan to 20,000,000 shares. On December 10, 2021, the Company filed a registration statement on Form S-8 that registered 34,650,120 shares issued under the 2011 Stock Incentive Plan and 2021 Equity Incentive Plan. Year Ended September 30, 2021 During the year ended September 30, 2021, the Company issued stock option grants to seventeen employees and consultants totaling 10,650,745 shares of common stock at an average price of $1.766 per share. The stock option grants expire in five years. Stock option grants totaling 9,145,745 vest when earned based on certain performance criteria and 1,505,000 option grants vest quarterly over 4 years, with nothing vesting in the first two quarters. No stock compensation expense has been recorded through September 30, 2021 for those options with performance milestones. During the year ended September 30, 2021, two consultants exercised stock option grants for 20,625 shares at $1.359 per share. During the year ended September 30, 2021, an employee forfeited a stock option grant for 120,000 shares at $3.30 per share. Year Ended September 30, 2020 The Company had the following stock option transactions during the year ended September 30, 2020: During the year ended September 30, 2020, the Company granted stock option grants to executives, directors and consultants for 3,085,000 shares with a weighted average exercise price of $1.142 per share. The grants expire in five years and generally vest quarterly over four years. Stock option grants totaling 2,630,000 shares of common stock are performance stock option grants and are not vested until the performance is achieved. No stock compensation expense has been recorded through September 30, 2020 for those options with performance milestones. During the year ended September 30, 2020, executives and employees voluntarily cancelled stock option grants for 2,739,477 shares with a weighted average exercise price of $2.593 per share. On November 9, 2019, a former employee exercised stock option grants on a cashless basis. The former employee received 73,191 shares of common stock for vested stock option grants totaling 93,750 shares. The stock option grant had an exercise price of $0.25 per share. There are currently 15,315,120 (including unearned stock option grants totaling 11,775,745 shares related to performance milestones) options to purchase common stock at an average exercise price of $1.565 per share outstanding as of September 30, 2021 under the 2011 Stock Incentive Plan. The Company recorded $1,028,522 and $1,702,085 of compensation expense, net of related tax effects, relative to stock options for the year ended September 30, 2021 and 2020 and in accordance with ASC 718. As of September 30, 2021, there is approximately $1,312,936, net of forfeitures, of total unrecognized costs related to employee granted stock options that are not vested. These costs are expected to be recognized over a period of approximately 3.82 years. Stock option activity for the years ended September 30, 2021 and 2020 was as follows: Weighted Average Options Exercise Price $ Outstanding as of September 30, 2019 4,532,668 $ 2.025 $ 9,180,369 Granted 3,085,000 1.142 3,522,400 Exercised (73,191 ) (0.250 ) (18,298 ) Forfeitures (2,739,477 ) (2.593 ) (7,103,921 ) Outstanding as of September 30, 2020 4,805,000 1.161 5,580,550 Granted 10,650,745 1.766 18,807,990 Exercised (20,625 ) (1.359 ) (28,031 ) Forfeitures (120,000 ) (3.300 ) (396,000 ) Outstanding as of September 30, 2021 15,315,120 $ 1.565 $ 23,964,509 The following table summarizes information about stock options outstanding and exercisable as of September 30, 2021: Weighted Weighted Weighted Average Average Average Range of Number Remaining Life Exercise Price Number Exercise Price Exercise Prices Outstanding In Years Outstanding Exerciseable Exerciseable $ 0.25 230,000 1.71 0.250 172,500 $ 0.250 1.10-1.25 3,074,375 3.15 1.108 445,456 1.105 1.28-1.53 9,480,745 3.58 1.499 993,750 1.307 1.79-3.67 2,530,000 4.64 2.192 108,750 1.895 15,315,120 3.82 $ 1.565 1,720,456 $ 1.316 There stock option grants of 15,315,120 shares as of September 30, 2021 with an aggregate intrinsic value of $14,916,905. Particle, Inc. Stock Incentive Plan On May 21, 2020, Particle approved a 2020 Stock Incentive Plan and reserved 8,000,000 shares under the Plan. The Plan requires vesting annually over four years, with no vesting in the first two quarters. During the year ended September 30, 2021, Particle approved a stock option grant to nine employees and consultants totaling 1,900,000 shares at an average of $0.80 per share. The stock option grant vests (i) 33.3% with the first shipment; (ii) 33.3% with $50 million in sales are achieved; and (iii) 33.4% after $200 million in sales are achieved. During the year ended September 30, 2021, Particle approved stock option grants to employees totaling 550,000 shares at $0.80 per share. The stock option grants vest annually over four years, with no vesting in the first two quarters. As of September 30, 2021 the 2020 Stock Incentive Plan, was terminated and all stock option grants were cancelled by the participants. The Company recorded $197,553 and $833,771 of compensation expense, net of related tax effects, relative to stock options for the years ended September 30, 2021 and 2020 and in accordance with ASC 718.

SIGNIFICANT AND OTHER TRANSACTI

SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES
SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES	10. SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES Transactions with Clayton Struve See Notes 7 and 8 for related party transactions with Clayton A. Struve. The Company owes Clayton A. Struve $1,071,000 under convertible promissory or OID notes. The Company recorded accrued interest of $84,671 and $79,062 as of June 30, 2022 and September 30, 2021, respectively. On May 3, 2022, the Company signed Amendments to the convertible promissory or OID notes, extending the due dates to September 30, 2022. Related Party Transactions with Ronald P. Erickson See Notes 7, 9, and 11 for related party transactions with Ronald P. Erickson. On December 16, 2021, the Company issued a stock option grant to Ronald P. Erickson for 1,000,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. Mr. Erickson and/or entities with which he is affiliated also have accrued compensation, travel and interest of approximately $274,640 and $421,599 as of June 30, 2022 and September 30, 2021, respectively. During the nine months ended June 30, 2022, the Company paid $120,000 of salaries to Mr. Erickson that were previously accrued and reported but were deferred. Related Party Transaction with Phillip A. Bosua See Notes 9 and 11 for related party transactions with Phillip A. Bosua. On December 16, 2021, the Company issued a stock option grant to Phillip A. Bosua for 1,300,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. As of December 31, 2021 the Company had recorded an accounts receivable-related party of $3,124,581 for the cash it expected to receive from the CEO’s personal digital account. The Company has established a digital wallet and corporate account at Circle in order to receive the Ethereum and then convert it to cash. The Company received $2,908,551 of Ethereum and recorded a reduction in value of $169,884 related to the decline in value of the Ethereum. The accounts receivable-related party was $46,146 as of June 30, 2022. As of June 30, 2022, accrued expenses include approximately $436,378 of expenses, primarily sales and use tax and other expenses. As of June 30, 2022 accrued expenses-related party include $799,353 of unpaid compensation that was due and payable to the CEO for the NFT revenue. This unpaid compensation was paid in July 2022 During 2021, approximately $1.3 million of the selling and transactional costs for the digital assets was paid through the CEO’s personal digital asset account including approximately $1.075 million which was paid to a consultant via the transfer of Ethereum. Related Party Transactions with Directors On January 5, 2022, the Company issued 30,000 shares each to three directors shares at an exercise price of $1.70 per share. On January 5, 2022, the Company issued 20,000 warrants to purchase common stock each to three directors shares at $1.70 per share. The warrants expire on January 5, 2027.	11. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES Transactions with Clayton Struve See Notes 7, 9 and 15 for related party transactions with Clayton A. Struve. On January 5, 2021, the Company extended the warrant expiration date to August 4, 2023 with Clayton A. Struve, a major investor in the Company: Warrant No./Class Issue Date No. Warrant Shares Exercise Price Original Expiration Date Amended Expiration Date Clayton Struve Warrant Series C Warrant W98 08-04-2016 1,785,715 $ 0.25 08-04-2021 08-04-2023 Clayton Struve Warrant Series F Warrant F-1 11-14-2016 187,500 $ 0.25 11-13-2021 11-13-2023 Clayton Struve Warrant Series F Warrant F-2 12-19-2016 187,500 $ 0.25 12-18-2021 12-18-2023 On January 28, 2021, Clayton A. Struve exercised warrants on a cashless basis for 889,880 shares of common stock at $0.25 per share, including warrants for 187,500 and 187,500 that were just extended as discussed above. The Company owes Clayton A. Struve $1,071,000 under convertible promissory or OID notes. On November 8, 2021, the Company signed Amendments to the convertible promissory or OID notes, extending the due dates to March 31, 2022. Mr. Struve invested $1,000,000 in the Debt Offering which closed in May 2019. On March 18, 2020, Mr. Struve received 1,080,000 shares of common stock related to the automatic conversion of the $1,000,000 invested in the Debt Offering. Related Party Transactions with Ronald P. Erickson See Notes 9, 10, 12 and 15 for related party transactions with Ronald P. Erickson. On October 4, 2019, Ronald P. Erickson voluntarily cancelled a stock option grant for 1,000,000 shares with an exercise price of $3.03 per share. The grant was related to performance and was not vested. On November 4, 2019, the Company granted a stock option grant to Ronald P. Erickson for 1,200,000 shares with an exercise price of $1.10 per share. The performance grant expires November 4, 2024 and vests upon uplisting to the NASDAQ or NYSE exchanges. On January 1, 2020, the Company issued 100,000 shares of restricted common stock to Ronald P. Erickson. The shares were issued in accordance with the 2011 Stock Incentive Plan and were valued at $1.90 per share, the market price of our common stock, or $190,000. On June 1, 2020, Mr. Erickson received a salary of $10,000 per month for work on Particle, Inc. This salary was cancelled as of August 15, 2021. On July 2, 2020, Particle issued a stock option grant for 1,500,000 shares at $0.10 per share to Ronald P. Erickson. The stock option grant vests (i) 33.3% upon issuance; (ii) 33.3% after the first sale; and (iii) 33.4% after one million in sales are achieved. The stock option grant was forfeited as of September 30, 2021. On December 15, 2020, the Company issued a fully vested warrant to Ronald P. Erickson for 2,000,000 shares of common stock. The five year warrant is exercisable for cash or non-cash at $1.53 per share and was valued using a Black-Scholes model at $1,811,691. On December 15, 2020, the Company issued two stock option grants to Ronald P. Erickson, one for 1,865,675 shares and one for 1,865,675 shares at an exercise price of $1.53 per share. The stock option grants expire in five years. The stock option grants vest when earned based on certain performance criteria. Mr. Erickson and/or entities with which he is affiliated also have accrued compensation, travel and interest of approximately $421,599 and $597,177 as of September 30, 2021 and 2020, respectively. During the year ended September 30, 2021, the Company paid $272,500 of salaries to Mr. Erickson that were previously accrued and reported but were deferred. On September 30, 2021, the Company approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to March 31, 2022. Related Party Transaction with Phillip A. Bosua See Notes 9, 10 and 12 for related party transactions with Phillip A. Bosua. On October 4, 2019, Philip A. Bosua voluntarily cancelled a stock option grant for 1,000,000 shares with an exercise price of $3.03 per share. The grants was related to performance and was not vested. On November 4, 2019, the Company granted a stock option grant to Philip A. Bosua for 1,200,000 shares with an exercise price of $1.10 per share. The performance grant expires November 4, 2024 and vests upon FDA approval of the UBAND blood glucose monitor. On January 1, 2020, the Company issued 150,000 shares of restricted common stock to Phillip A. Bosua. The shares were issued in accordance with the 2011 Stock Incentive Plan and were valued at $1.90 per share, the market price of the Company’s common stock, or $285,000. On June 1, 2020, Mr. Bosua received a salary of $10,000 per month for work on Particle, Inc. This salary was cancelled as of August 15, 2021. On July 2, 2020, Particle issued a stock option grant for 1,500,000 shares at $0.10 per share to Philip A. Bosua. The stock option grant vests (i) 33.3% upon issuance; (ii) 33.3% after the first sale; and (iii) 33.4% after one million in sales are achieved. The stock option grant was forfeited as of September 30, 2021. On December 15, 2020, the Company issued two stock option grant to Phillip A. Bosua, one for 2,132,195 shares and one for 2,132,200 shares at an exercise price of $1.53 per share. The stock option grants expire in five years. The stock option grants vest when earned based on certain performance criteria. On March 18, 2021, the Company approved a $250,000 bonus for Mr. Bosua. The bonus was paid during April 2021. Stock Issuances and Cancellations to Named Executive Officers and Directors On November 4, 2019, the Company granted stock option grants to two directors totaling 105,000 shares with an exercise price of $1.10 per share. The stock option grants expire in five years. The stock option grants vested immediately. On January 1, 2020, the Company issued 120,000 shares of restricted common stock to three directors. The shares were issued in accordance with the 2011 Stock Incentive Plan and were valued at $1.90 per share, the market price of the Company’s common stock, or $228,000. On January 15, 2021, the Company issued 30,000 shares each to three directors shares at an exercise price of $2.00 per share. On January 15, 2021, the Company issued 20,000 warrants to purchase common stock each to three directors shares at $2.00 per share. The warrants expire on January 15, 2026.

COMMITMENTS CONTINGENCIES AND L

COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS
COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS	11. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS Legal Proceedings The Company may from time to time become a party to various legal proceedings arising in the ordinary course of our business. The Company is currently not a party to any pending legal proceeding that is not ordinary routine litigation incidental to our business. Employment Agreements Phillip A. Bosua, Chief Executive Officer On April 10, 2018, we entered into an employment agreement with Mr. Bosua reflecting his appointment as Chief Executive Officer. The employment agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the Employment Agreement with at least ninety (90) days prior to the end of the Initial Term or renewal term. Mr. Bosua was paid a base salary of $225,000 per year, received 500,000 shares of common stock valued at $0.33 per share and may be entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. The employment agreement provides for severance pay equal to 12 months of base salary if Mr. Bosua is terminated without “cause” or voluntarily terminates his employment for “good reason.” During the years ended September 30, 2021 and 2020, our compensation committee and our board of directors compensated Mr. Bosua with an annual salary of $240,000 from October 1, 2019 to May 1, 2020. From May 1, 2020 to March 31, 2021, the annual compensation was $260,000. From April 1, 2021 to September 30, 2021, the annual compensation was $350,000. The compensation committee and the board of directors of Particle compensated Phillip A. Bosua with an annual salary of $120,000 from June 1, 2020 to August 15, 2021. Mr. Bosua will be entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. If our company terminates Mr. Bosua’s employment at any time prior to the expiration of the term without cause, as defined in the employment agreement, or if Mr. Bosua terminates his employment at any time for “good reason” or due to a “disability,” Mr. Bosua will be entitled to receive (i) his base salary amount for one year; and (ii) medical benefits for eighteen months. Peter Conley, Chief Financial Officer and Senior Vice President, Intellectual Property On May 13, 2022, we entered into an employment agreement with Mr. Conley reflecting his appointment as our Chief Financial Officer and Senior Vice President, Intellectual Property. The employment agreement is at will, meaning either we or Mr. Conley may terminate the employment relationship at any time, with or without cause, upon written notice to the other party. Under the terms of this agreement, Mr. Conley has an annualized base salary of $300,000, and the base salary will be paid periodically in accordance with our normal payroll practice. Mr. Conley may also be entitled to bonuses from time to time as determined by our board of directors or our Compensation Committee in their sole discretion. The employment agreement provides that Mr. Conley is eligible for equity awards under our 2021 Equity Incentive Plan or by agreement outside the plan. The employment agreement provides for severance pay equal to 12 months of then-in-effect base salary if Mr. Conley is terminated without “cause” or voluntarily terminates his employment for “good reason,” as defined in the employment agreement. Mr. Conley is eligible to participate in of all our employee benefit plans, policies and arrangements that are applicable to other executive officers, as such plans, policies and arrangements may exist or change from time to time at our discretion. We will reimburse Mr. Conley for reasonable travel, entertainment and other expenses he incurs in the furtherance of his duties under this agreement. Ronald P. Erickson, Chairman of the Board On April 10, 2018, we entered into an amended employment agreement for Ronald P. Erickson which amends our employment agreement with him dated July 1, 2017. The initial one-year term of this amended agreement expired March 21, 2019, and automatically extends for additional one (1) year periods unless either party delivers written notice of such party’s intention to terminate the agreement at least ninety (90) days prior to the end of the renewal term. During the years ended September 30, 2021 and 2020, our compensation committee and our board of directors compensated Mr. Erickson with an annual salary of $195,000 from October 1, 2019 to May 1, 2020. From May 1, 2020 to March 31, 2021, the annual compensation was $215,000. From April 1, 2021 to September 30, 2021, the annual compensation was $300,000. The compensation committee and the board of Particle compensated Mr. Erickson with an annual salary of $120,000 from June 1, 2020 to August 15, 2021. Mr. Erickson will be entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. If our company terminates Mr. Erickson’s employment at any time prior to the expiration of the term without cause, as defined in the employment agreement, or if Mr. Erickson terminates his employment at any time for “good reason” or due to a “disability,” Mr. Erickson will be entitled to receive (i) his base salary amount for one year; and (ii) medical benefits for eighteen months. Properties and Operating Leases The Company is obligated under the following leases for its various facilities. Corporate Offices On April 13, 2017, the Company leased our executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. The Company leases 943 square feet and the current net monthly payment is $3,334. The monthly payment increases approximately 3% each year and the lease expires on May 31, 2022. On October 31, 2021, we extended the lease from June 1, 2022 to May 31, 2023 at $2,986 per month. Lab Facilities and Executive Offices On February 1, 2019, the Company leased its lab facilities and executive offices located at 915 E Pine Street, Suite 212, Seattle, WA 98122. The Company leases 2,642 square feet and the net monthly payment at September 30, 2021 is $8,697. The monthly payment increases approximately 3% annually each year on July 1. The lease expires on June 30, 2024. On October 11, 2021, the Company entered into First Amendment of Lease and added 1,030 square feet for year for $5,000 per month. The space will be utilized for clinical trials.	12. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS Legal Proceedings The Company may from time to time become a party to various legal proceedings arising in the ordinary course of our business. The Company is currently not a party to any pending legal proceeding that is not ordinary routine litigation incidental to our business. Employment Agreement with Phillip A. Bosua, Chief Executive Officer Phillip A. Bosua was appointed our Chief Executive Officer on April 10, 2018. Previously, Mr. Bosua served as the Company’s Chief Product Officer since August 2017. The Company entered into a Consulting Agreement with Mr. Bosua’s company, Blaze Clinical on July 7, 2017. From September 2012 to February 2015, Mr. Bosua was the founder and Chief Executive Officer of LIFX Inc. (where he developed and marketed an innovative “smart” light bulb) and from August 2015 until February 2016 was Vice President Consumer Products at Soraa (which markets specialty LED light bulbs). From February 2016 to July 2017, Mr. Bosua was the founder and CEO of RAAI, Inc. (where he continued the development of his smart lighting technology). From May 2008 to February 2013 he was the Founder and CEO of LimeMouse Apps, a leading developer of applications for the Apple App Store. On April 10, 2018, we entered into an Employment Agreement with Mr. Bosua reflecting his appointment as Chief Executive Officer. The Employment Agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the Employment Agreement with at least ninety (90) days prior to the end of the Initial Term or renewal term. Mr. Bosua was paid a base salary of $225,000 per year, received 500,000 shares of common stock valued at $0.33 per share and may be entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. The Employment Agreement provides for severance pay equal to 12 months of base salary if Mr. Bosua is terminated without “cause” or voluntarily terminates his employment for “good reason.” During the years ended September 30, 2021 and 2020, the Compensation Committee and the Board compensated Phillip A. Bosua, its Chief Executive Officer, with an annual salary of $240,000 from October 1, 2019 to May 1, 2020. May 1, 2020 to March 31, 2021, the annual compensation was $260,000. From April 1, 2021 to September 30, 2021, the annual compensation was $350,000. The Compensation Committee and the Board of Particle, Inc. compensated Phillip A. Bosua with an annual salary of $120,000 from June 1, 2020 to August 15, 2021. Mr. Bosua will be entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. If the Company terminates Mr. Bosua’s employment at any time prior to the expiration of the Term without Cause, as defined in the Employment Agreement, or if Mr. Bosua terminates his employment at any time for “Good Reason” or due to a “Disability,” Mr. Bosua will be entitled to receive (i) his Base Salary amount for one year; and (ii) medical benefits for eighteen months. Employment Agreement with Ronald P. Erickson, Chairman of the Board and Interim Chief Financial Officer On April 10, 2018, we entered into an Amended Employment Agreement for Ronald P. Erickson which amends the Employment Agreement dated July 1, 2017. The Agreement expires March 21, 2019. automatically be extended for additional one (1) year periods unless either Party delivers written notice of such Party’s intention to terminate this Agreement at least ninety (90) days prior to the end of the Initial Term or renewal term. During the years ended September 30, 2021 and 2020, the Compensation Committee and the Board compensated Ronald P. Erickson, its Chairman of the Board and Interim Financial Officer, with an annual salary of $195,000 from October 1, 2019 to May 1, 2020. From May 1, 2020 to March 31, 2021, the annual compensation was $215,000. From April 1, 2021 to September 30, 2021, the annual compensation was $300,000. The Compensation Committee and the Board of Particle Inc. compensated Ronald P. Erickson with an annual salary of $120,000 from June 1, 2020 to August 15, 2021. Mr. Erickson will be entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. If the Company terminates Mr. Erickson’s employment at any time prior to the expiration of the Term without Cause, as defined in the Employment Agreement, or if Mr. Erickson terminates his employment at any time for “Good Reason” or due to a “Disability,” Mr. Erickson will be entitled to receive (i) his Base Salary amount for one year; and (ii) medical benefits for eighteen months. Properties and Operating Leases The Company is obligated under the following leases for its various facilities. Corporate Offices On April 13, 2017, the Company leased its executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. The Company leases 943 square feet and the current net monthly payment is $3,334. The monthly payment increases approximately 3% each year and the lease expires on May 31, 2022. Lab Facilities and Executive Offices On February 1, 2019, the Company leased its lab facilities and executive offices located at 915 E Pine Street, Suite 212, Seattle, WA 98122. We lease 2,642 square feet and the net monthly payment at September 30, 2021 is $8,697. The monthly payment increases approximately 3% annually each year on July 1. The lease expires on June 30, 2024.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Sep. 30, 2021
INCOME TAXES
INCOME TAXES	13. INCOME TAXES The Company has incurred losses since inception, which have generated net operating loss carryforwards. The net operating loss carryforwards arise from United States sources. Losses arising from United States taxable operations were approximately $6.5 million and $5.1 million for the years ended September 30, 2021 and 2020. The Company has Federal net operating loss carryforwards of approximately $43.8 million which expire in 2028-2041. Because it is not more likely than not that sufficient tax earnings will be generated to utilize the net operating loss carryforwards, a corresponding valuation allowance equal to 100% of the gross deferred tax asset of approximately $9.7 million and $8.0 million was established as of September 30, 2021 and 2020. The Company does not recognize the majority of state tax loss operating loss carryforwards as a deferred tax asset given it no longer has any operation in that state. Under the Tax Reform Act of 1986, the amounts of, and benefits from, net operating losses may be limited in certain circumstances, including a change in control. Section 382 of the Internal Revenue Code generally imposes an annual limitation on the amount of net operating loss carryforwards that may be used to offset taxable income when a corporation has undergone significant changes in its stock ownership. There can be no assurance that the Company will be able to utilize any net operating loss carryforwards in the future. The Company is subject to possible tax examination for the years 2016 through 2021. The principal components of the Company’s deferred tax assets at September 30, 2021 and 2020 are as follows: 2021 2020 Net operating loss carryforward $ 8,051,000 $ 6,536,000 Stock based compensation 975,000 1,196,000 Intangibles 276,000 305,000 Accruals and reserves 399,000 11,000 Total deferred tax asset 9,701,000 8,048,000 Valuation allowance (9,701,000 ) (8,048,000 ) Net deferred tax assets $ - $ - Change in valuation allowance during the year $ (1,653,000 ) $ (1,092,357 ) A reconciliation of the United States Federal Statutory rate to the Company’s effective tax rate for the years ended September 30, 2021 and 2020 are as follows. For the year ended September 30, 2021 and 2020, the Company’s effective tax rate differs from the federal statutory rate principally due to non deductible warrant interest expense plus an increase in the deferred tax asset valuation allowance. 2021 2020 Income tax provision at statutory rate -21.0 % -21.0 % Warrant interest expense 12 % 9 % Change in valuation allowance 7 % 9 % Prior year true up 2 % 3 % Effective tax rate 0 % 0 % As of September 30, 2021, there were no uncertain tax positions. Management does not anticipate any future adjustments in the next twelve months which would result in a material change to its tax position. For the years ended September 30, 2021 and 2020, the Company did not have any interest and penalties.

SEGMENT REPORTING

SEGMENT REPORTING	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
SEGMENT REPORTING
SEGMENT REPORTING	12. SEGMENT REPORTING The management of the Company considers the business to currently have three operating segments (i) the development of the Bio-RFID™” and “ChromaID” technologies; (ii) Particle, Inc. technology; and (iii) AI sales of NFT products. Particle commenced operations in the three months ended June 30, 2020. AI commenced operations during the nine months ended June 30, 2022. The reporting for the three and nine months ended June 30, 2022 and 2021 was as follows (in thousands): Segment Operating Segment Segment Revenue (Loss) Assets Three Months Ended June 30, 2022 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ (2,838 ) $ 7,522 Particle, Inc. technology - (23 ) - Digital asset sales - (164 ) 2,105 Total segments $ - $ (3,025 ) $ 9,627 Three Months Ended June 30, 2021 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ (1,719 ) $ 13,993 Particle, Inc. technology - (144 ) 33 Total segments $ - $ (1,863 ) $ 14,026 Segment Operating Segment Segment Revenue Profit (Loss) Assets Nine Months Ended June 30, 2022 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ (7,616 ) $ 7,522 Particle, Inc. technology - (45 ) - Digital asset sales 4,360 923 2,105 Total segments $ 4,360 $ (6,738 ) $ 9,627 Nine Months Ended June 30, 2021 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ (7,088 ) $ 13,993 Particle, Inc. technology - (940 ) 33 Total segments $ - $ 8,028 ) $ 14,026 During the nine months ended June 30, 2022 and 2021, the Company incurred non-cash expenses related to operations of $9,242,544 and $12,203,424, respectively.	14. SEGMENT REPORTING The management of the Company considers the business to currently have two operating segments (i) the development of the Bio-RFID™” and “ChromaID™” technologies; (ii) Particle, Inc. technology. ) TransTech, a distributor of products for employee and personnel identification and authentication was shut down on June 30, 2020. Particle commenced operations in the three months ended June 30, 2020. The reporting for the year ended September 30, 2021 and 2020 was as follows (in thousands): Gross Operating Segment Segment Revenue Margin (Loss) Assets Year Ended September 30, 2021 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ - $ (9,373 ) $ 12,867 Particle, Inc. technology - - (1,073 ) 22 TransTech distribution business - - - - Total segments $ - $ - $ (10,446 ) $ 12,889 Year Ended September 30, 2020 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ - $ (5,481 ) $ 4,360 Particle, Inc. technology - - (1,280 ) 322 TransTech distribution business 122 70 (65 ) - Total segments $ 122 $ 70 $ (6,826 ) $ 4,682 During years ended September 30, 2021 and 2020, the Company incurred non-cash expenses related to operations of $3,979,584 and $2,990,072.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS The Company evaluated subsequent events, for the purpose of adjustment or disclosure, up through the date the financial statements were issued. Subsequent to June 30, 2022, there were the following material transactions that require disclosure: On July 6, 2022, the Company issued a stock option grant to an employee for 150,000 shares at an exercise price of $2.24 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years after two quarters.	15. SUBSEQUENT EVENTS The Company evaluated subsequent events, for the purpose of adjustment or disclosure, up through the date the financial statements were issued. Subsequent to September 30, 2021, there were the following material transactions that require disclosure: Annual Shareholder Meeting On October 15, 2021, the Company held its annual shareholder meeting. The Company’s shareholders approved and adopted various motions as detailed in the Company’s Form 8-K that was filed with the SEC on October 19, 2021. 2021 Equity Incentive Plan On October 15, 2021, at the annual shareholder meeting held on October 15, 2021, the 2021 Equity Incentive Plan was adopted and approved, increasing size of the stock available under the Stock Option Plan to 20,000,000 shares. On December 10, 2021, the Company filed a registration statement on Form S-8 that registered 34,650,120 shares issued under the 2011 Stock Incentive Plan and 2021 Equity Incentive Plan. Second Amended and Restated Bylaws On October 15, 2021, the shareholders of the Company approving the Second Amended and Restated Bylaws effective October 15, 2021. Lease Modifications On April 13, 2017, the Company leased its executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. The Company leases 943 square feet and the current net monthly payment is $3,334. The monthly payment increases approximately 3% each year and the lease expires on May 31, 2022. On October 31, 2021, the Company extended the lease from June 1, 2022 to May 31, 2023 at $2,986 per month. On February 1, 2019, the Company leased its lab facilities and executive offices located at 915 E Pine Street, Suite 212, Seattle, WA 98122. The Company leases 2,642 square feet and the net monthly payment at September 30, 2021 is $8,697. The monthly payment increases approximately 3% annually each year on July 1. The lease expires on June 30, 2024. On October 11, 2021, the Company entered into First Amendment of Lease and added 1,030 square feet for year for $1,000 for $5,000 per month. The space will be utilized for clinical trials. Extension of Convertible Promissory Notes with Clayton A. Struve On November 8, 2021, the Company signed Amendments to the convertible promissory or OID notes, extending the due dates to March 31, 2022. Certificate of Amendment to Articles of Incorporation On December 6, 2021, the Company received approval from the State of Nevada for a Certificate of Amendment to the Articles of Incorporation related to the increase in the number of authorized common shares. AI Revenue On December 16, 2021, the Company, announced the Company’s Artificial Intelligence (AI) Deep Learning Platform has generated initial revenue of approximately $4.2 million from Non-Fungible Token (NFT) sales. Note Payable-PPP Loans On April 30, 2020, the Company received $226,170 under the Paycheck Protection Program of the U.S. Small Business Administration’s 7(a) Loan Program pursuant to the Coronavirus, Aid, Relief and Economic Security Act (CARES Act), Pub. Law 116-136, 134 Stat. 281 (2020). The Company filed the application for the loan forgiveness during the three months ended December 31, 2021 and the Company is expecting approval by the SBA. On February 1, 2021, the Company received $205,633 under the Paycheck Protection Program of the U.S. Small Business Administration’s 7(a) Loan Program pursuant to the Coronavirus, Aid, Relief and Economic Security Act (CARES Act), Pub. Law 116-136, 134 Stat. 281 (2020). The Company filed the application for the loan forgiveness during the three months ended December 31, 2021 and the Company is expecting approval by the SBA. Stock Option Exercises and Issuances The Company issued 803,361 shares of common stock related to warrant and stock option exercises and received $768,830. The Compensation committee issued stock option grants to seven employees and three consultants for 910,000 shares at an exercise price of $2.09 per share. The stock option grants expire in five years. The stock option grant vests quarterly over four years. On December 16, 2021, the Company issued a stock option grant to Ronald P. Erickson for 1,000.000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. On December 16, 2021, the Company issued a stock option grant to Phillip A. Bosua for 1,300,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. On December 16, 2021, the Company approved 30,000 shares each to three directors shares at terms to be determined during January 2022. On December 16, 2021, the Company issued 20,000 warrants to purchase common stock each to three directors shares at terms to be determined during January 2022.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS
Basis of Presentation	Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation	Principles of Consolidation
Cash and Cash Equivalents	Cash and Cash Equivalents	Cash and Cash Equivalents
Equipment	Equipment	Equipment
Long-Lived Assets	Long-Lived Assets	Long-Lived Assets
Intangible Assets	Intangible Assets	Intangible Assets
Research and Development Expenses	Research and Development Expenses The Company’s current research and development efforts are primarily focused on improving our Bio-RFID technology, extending its capacity and developing new and unique applications for this technology. As part of this effort, the Company conducts on-going laboratory testing to ensure that application methods are compatible with the end-user and regulatory requirements, and that they can be implemented in a cost-effective manner. The Company also is actively involved in identifying new applications. The Company’s current internal team along with outside consultants has considerable experience working with the application of the Company’s technologies and their applications. The Company engages third party experts as required to supplement our internal team. The Company believes that continued development of new and enhanced technologies is essential to our future success. The Company incurred expenses of $3,406,996, $3,969,972 and $2,033,726 for the nine months ended June 30, 2022 and the years ended September 30, 2021 and 2020, respectively, on development activities.	Research and Development Expenses The Company’s current research and development efforts are primarily focused on improving our Bio-RFID technology, extending its capacity and developing new and unique applications for this technology. As part of this effort, the Company conducts on-going laboratory testing to ensure that application methods are compatible with the end-user and regulatory requirements, and that they can be implemented in a cost-effective manner. The Company also is actively involved in identifying new applications. The Company’s current internal team along with outside consultants has considerable experience working with the application of the Company’s technologies and their applications. The Company engages third party experts as required to supplement our internal team. The Company believes that continued development of new and enhanced technologies is essential to our future success. The Company incurred expenses of $3,969,972 and $2,033,726 for the year ended September 30, 2021 and 2020, respectively, on development activities.
Advertising	Advertising	Advertising
Fair Value Measurements and Financial Instruments	Fair Value Measurements and Financial Instruments Fair Value Measurement and Disclosures Level 1 - Quoted prices in active markets for identical assets and liabilities; Level 2 - Inputs other than level one inputs that are either directly or indirectly observable; and. Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of June 30, 2022 and September 30, 2021 are based upon the short-term nature of the assets and liabilities. The Company has a money market account which is considered a level 1 asset. The balance as of June 30, 2022 and September 30, 2021 was $6,041,016 and $12,217,714, respectively.	Fair Value Measurements and Financial Instruments Fair Value Measurement and Disclosures Level 1 - Quoted prices in active markets for identical assets and liabilities; Level 2 - Inputs other than level one inputs that are either directly or indirectly observable; and. Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of September 30, 2021 and 2020 are based upon the short-term nature of the assets and liabilities. The Company has a money market account which is considered a level 1 asset. The balance as of September 30, 2021 and 2020 was $12,217,714 and $4,252,959, respectively.
Derivative Financial Instruments	Derivative Financial Instruments - The Company determined that the conversion features for purposes of bifurcation within convertible notes payable were immaterial and there was no derivative liability to be recorded as of June 30, 2022 and September 30, 2021.	Derivative Financial Instruments - The Company determined that the conversion features for purposes of bifurcation within its currently outstanding convertible notes payable were immaterial and there was no derivative liability to be recorded as of September 30, 2021 and 2020.
Stock Based Compensation	Stock Based Compensation	Stock Based Compensation
Convertible Securities	Convertible Securities	Convertible Securities
Net Loss per Share	Net Loss per Share As of June 30, 2021, the Company had 33,719,669 shares of common stock issued and outstanding. As of June 30, 2021, there were options outstanding for the purchase of 14,650,120 common shares (including unearned stock option grants totaling 11,775,745 shares related to performance targets), warrants for the purchase of 23,169,587 common shares, and 8,108,356 shares of the Company’s common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 16,124,764 common shares (9,020,264 common shares at the current price of $0.25 per share and 7,104,500 common shares at the current price of $2.00 per share) reserved and are issuable upon conversion of convertible debentures of $16,464,066. All of which could potentially dilute future earnings per share but are excluded from the June 30, 2021 calculation of net loss per share because their impact is antidilutive.	Net Loss per Share As of September 30, 2020, there were options outstanding for the purchase of 4,805,000 common shares (including unearned stock option grants totaling 2,630,000 shares related to performance targets), warrants for the purchase of 20,016,367common shares, and 8,108,356 shares of the Company’s common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 14,659,764 common shares (9,020,264 common shares at the current price of $0.25 per share and 5,639,500 common shares at the current price of $1.00 per share) and are issuable upon conversion of convertible debentures of $7,894,566. All of which could potentially dilute future earnings per share but excluded from the September 30, 2020 calculation of net loss per share because their impact is antidilutive.
Comprehensive Loss	Comprehensive loss	Comprehensive loss
Dividend Policy	Dividend Policy	Dividend Policy
Use of Estimates	Use of Estimates	Use of Estimates
Recent Accounting Pronouncements	Recent Accounting Pronouncements Debt -- debt with Conversion and Other Options (Subtopic470-20) and Derivatives and Hedging --Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity Based on the Company’s review of accounting standard updates issued since the filing of the June 30, 2022 Form 10-Q, there have been no other newly issued or newly applicable accounting pronouncements that have had, or are expected to have, a significant impact on the Company’s consolidated financial statements. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.	In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt --debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging --Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity Based on the Company’s review of accounting standard updates issued since the filing of the 2021 Form 10-K, there have been no other newly issued or newly applicable accounting pronouncements that have had, or are expected to have, a significant impact on the Company’s consolidated financial statements. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.
Revenue Recognition	Revenue Recognition · identification of the contract, or contracts, with the customer; · identification of the performance obligations in the contract; · determination of the transaction price; · allocation of the transaction price to the performance obligations in the contract; and · recognition of the revenue when, or as, the Company satisfies a performance obligation. Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. During the nine months ended June 30, 2022, the Company’s artificial intelligence (AI) Deep Learning Platform began generating revenue from digital asset sales of NFT’s. The Company engineering team, using its research date, AI and proprietary algorithms, produced NFT’s in the form of digital art. The NFT’s produced had no recorded cost basis.
Digital Asset Sales	Digital Asset Sales - After the sale of the NFT, the Ethereum is converted to US dollars as soon as practically possible. The Company records the total value of the gross NFT sale in revenue. Costs incurred in connection with the NFT transaction are recorded in the statement of operations as Selling and Transactional Cost of Digital Assets and include costs to outside consultants, estimated employee and CEO special bonus compensation, digital asset conversion losses and estimated sales and use tax. The amount totaled $164,093 and $3,436,955 for the three and nine months ended June 30, 2022, respectively.

FIXED ASSETS (Tables)

FIXED ASSETS (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
PROPERTY AND EQUIPMENT
Schedule of Property and equipment	Estimated June 30, September 30, Useful Lives 2022 2021 Machinery and equipment 2-3 years $ 1,498,355 $ 654,798 Leasehold improvements 5 years 3,612 3,612 Furniture and fixtures 5 years 26,855 26,855 Less: accumulated depreciation (575,444 ) (356,761 ) $ 953,378 $ 328,504	Estimated Useful Lives September 30, 2021 September 30, 2020 Machinery and equipment 2-3 years $ 654,798 $ 355,272 Leasehold improvements 5 years 3,612 3,612 Furniture and fixtures 5 years 26,855 26,855 Less: accumulated depreciation (356,761 ) (257,068 ) $ 328,504 $ 128,671

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
PROPERTY AND EQUIPMENT
Schedule of Property and equipment	Estimated June 30, September 30, Useful Lives 2022 2021 Machinery and equipment 2-3 years $ 1,498,355 $ 654,798 Leasehold improvements 5 years 3,612 3,612 Furniture and fixtures 5 years 26,855 26,855 Less: accumulated depreciation (575,444 ) (356,761 ) $ 953,378 $ 328,504	Estimated Useful Lives September 30, 2021 September 30, 2020 Machinery and equipment 2-3 years $ 654,798 $ 355,272 Leasehold improvements 5 years 3,612 3,612 Furniture and fixtures 5 years 26,855 26,855 Less: accumulated depreciation (356,761 ) (257,068 ) $ 328,504 $ 128,671

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Sep. 30, 2021
INTANGIBLE ASSETS
Schedule of intangible assets	Estimated September 30, September 30, Useful Lives 2021 2020 Technology 3 years $ 520,000 $ 520,000 Less: accumulated amortization (520,000 ) (418,886 ) Intangible assets, net $ - $ 101,114

LEASES (Tables)

LEASES (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
LEASES
Summary of minimum future lease payments	Years Ended June 30, $ 2023 $ 156,253 2024 118,602 Total remaining payments 274,855 Less Imputed Interest (12,629 ) Total lease liability $ 262,226	Years Ended September 30, $ 2022 $ 128,987 2023 107,662 2024 73,095 2025 - 2026 - Total Remaining Payments 309,744 Of which Imputed Interest (19,203 ) Total Lease Liability $ 290,541

CONVERTIBLE NOTES PAYABLE AND_2

CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE
Schedule of convertible notes	June 30, 2022 September 30, 2021 Convertible note- Clayton A. Struve $ 1,071,000 $ 1,071,000 Convertible note- Ronald P. Erickson and affiliates 1,184,066 1,184,066 2020 Convertible notes - 5,639,500 2021 Convertible notes 14,209,000 14,209,000 Boustead fee refund (originally booked as contra debt) - 50,000 Less conversions of notes (14,209,000 ) (5,639,500 ) Less debt discount - BCF - (4,308,337 ) Less debt discount - warrants - (1,957,590 ) Less debt discount - warrants issued for services - (1,056,984 ) $ 2,255,066 $ 9,191,155	September 30, 2021 September 30, 2020 Convertible note- Clayton A. Struve $ 1,071,000 $ 1,071,000 Convertible note- Ronald P. Erickson and affiliates 1,184,066 1,184,066 2019 Convertible notes 4,242,490 4,242,490 2020 Convertible notes 5,639,500 5,639,500 Q2 2021 Convertible notes 14,209,000 - Boustead fee refund (originally booked as contra debt) 50,000 50,000 Less conversions of notes (9,881,990 ) (4,242,490 ) Less debt discount - BCF (4,308,337 ) (2,127,894 ) Less debt discount - warrants (1,957,590 ) (1,025,512 ) Less debt discount - warrants issued for services (1,056,984 ) (823,582 ) $ 9,191,155 $ 3,967,578
Schedule of extension of warrant agreement	Warrant No./Class Issue Date No. Warrant Shares Exercise Price Original Expiration Date Amended Expiration Date Clayton A. Struve Warrant 08-14-2017 1,440,000 $ 0.25 08-13-2023 08-13-2024 Clayton A. Struve Warrant 12-12-2017 1,200,000 $ 0.25 12-11-2023 12-11-2024 Clayton A. Struve Warrant 08-04-2016 1,785,715 $ 0.25 08-04-2023 08-04-2024 Clayton A. Struve Warrant 02-28-2018 1,344,000 $ 0.25 02-28-2023 02-28-2024 June 30, 2022 Weighted Weighted Weighted Average Average Average Number of Remaining Exercise Shares Exercise Warrants Life ( In Years) Price Exerciseable Price 10,729,381 4.79 $ 0.250 10,729,381 $ 0.250 6,547,207 2.59 1.20-1.85 6,547,207 1.20-1.85 4,364,925 3.77 2.00-2.40 4,364,925 2.00-2.40 10,000 1.00 4.080 10,000 4.080 21,651,513 3.43 $ 1.003 21,651,513 $ 1.003
Summarizes information about warrants outstanding	June 30, 2022 Weighted Average Exercise Shares Price Outstanding at beginning of period 22,564,255 $ 0.998 Issued 60,000 - Exercised (863,986 ) (0.919 ) Forfeited - - Expired (108,756 ) (1.000 ) Outstanding at end of period 21,651,513 $ 1.003 Exerciseable at end of period 21,651,513

EQUITY (Tables)

EQUITY (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
EQUITY
Warrant activity	March 31, 2022      Weighted      Average      Exercise   Shares  Price Outstanding at beginning of period  22,564,255  $0.998 Issued  60,000   - Exercised  (801,486)  (0.956)Forfeited  -   - Expired  (108,756)  (1.000)Outstanding at end of period  21,714,013  $1.001 Exerciseable at end of period  21,714,013	September 30, 2021 Weighted Average Exercise Shares Price Outstanding at beginning of period 20,016,367 $ 0.556 Issued 6,608,789 2.117 Exercised (3,676,542 ) (0.582 ) Forfeited (384,359 ) (1.155 ) Expired - - Outstanding at end of period 22,564,255 $ 0.998 Exerciseable at end of period 22,564,255
Warrants outstanding and exercisable	March 31, 2022    Weighted  Weighted     Weighted    Average  Average     Average Number of  Remaining   Exercise  Shares   Exercise Warrants  Life ( In Years)  Price  Exercisable  Price  10,779,381   1.02  $0.250   10,779,381  $0.250                     6,559,707   2.84   1.20-1.85    6,559,707   1.20-1.85   4,364,925   4.00   2.00-2.40    4,364,925   2.00-2.40   10,000   1.25   4.080   10,000   4.080  21,714,013   3.17  $1.001   21,714,013  $1.001	September 30, 2021 Weighted Weighted Weighted Average Average Average Number of Remaining Exercise Shares Exercise Warrants Life ( In Years) Price Exerciseable Price 10,829,381 1.24 $ 0.250 10,829,381 $ 0.250 847,742 0.12 1.000 847,742 1.000 6,512,207 3.32 1.20-1.85 6,512,207 1.20-1.85 4,364,925 4.50 2.00-2.40 4,364,925 2.00-2.40 10,000 1.75 4.080 10,000 4.080 22,564,255 3.49 $ 0.998 22,564,255 $ 0.998
Weighted average assumptions relating to the valuation of the Company's warrants		Dividend yield 0 % Expected life 3-5 years Expected volatility 140 % Risk free interest rate 0.37 %

STOCK INCENTIVE PLANS (Tables)

STOCK INCENTIVE PLANS (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
EQUITY
Stock option activity	Weighted Average Options Exercise Price Proceed $ Outstanding as of October 1, 2019 4,532,668 $ 2.025 $ 9,180,369 Granted 3,085,000 1.142 3,522,400 Exercised (73,191 ) (0.250 ) (18,298 ) Forfeitures (2,739,477 ) (2.593 ) (7,103,921 ) Outstanding as of September 30, 2020 4,805,000 1.161 5,580,550 Granted 10,650,745 1.766 18,807,990 Exercised (20,625 ) (1.359 ) (28,031 ) Forfeitures (120,000 ) (3.300 ) (396,000 ) Outstanding as of September 30, 2021 15,315,120 1.565 23,964,509 Granted 6,446,000 1.805 11,632,130 Exercised (8,750 ) (1.564 ) (13,688 ) Forfeitures (825,000 ) (1.838 ) (1,516,150 ) Outstanding as of June 30, 2022 20,927,370 $ 1.628 $ 34,066,802	Weighted Average Options Exercise Price $ Outstanding as of September 30, 2019 4,532,668 $ 2.025 $ 9,180,369 Granted 3,085,000 1.142 3,522,400 Exercised (73,191 ) (0.250 ) (18,298 ) Forfeitures (2,739,477 ) (2.593 ) (7,103,921 ) Outstanding as of September 30, 2020 4,805,000 1.161 5,580,550 Granted 10,650,745 1.766 18,807,990 Exercised (20,625 ) (1.359 ) (28,031 ) Forfeitures (120,000 ) (3.300 ) (396,000 ) Outstanding as of September 30, 2021 15,315,120 $ 1.565 $ 23,964,509
Summarize information about particle stock option and exercisable		Weighted Weighted Weighted Average Average Average Range of Number Remaining Life Exercise Price Number Exercise Price Exercise Prices Outstanding In Years Outstanding Exerciseable Exerciseable $ 0.25 230,000 1.71 0.250 172,500 $ 0.250 1.10-1.25 3,074,375 3.15 1.108 445,456 1.105 1.28-1.53 9,480,745 3.58 1.499 993,750 1.307 1.79-3.67 2,530,000 4.64 2.192 108,750 1.895 15,315,120 3.82 $ 1.565 1,720,456 $ 1.316
Stock options outstanding and exercisable	Weighted Weighted Weighted Average Average Average Range of Number Remaining Life Exercise Price Number Exercise Price Exercise Prices Outstanding In Years Outstanding Exerciseable Exerciseable $ 0.25 230,000 0.96 $ 0.250 201,250 $ 0.250 1.10-1.25 2,930,625 2.35 1.101 548,307 1.105 1.28-1.67 12,330,745 2.46 1.503 1,175,521 1.303 1.79-3.67 5,436,000 4.25 1.195 665,063 1.917 20,927,370 4.15 1.628 2,590,141 $ 1.241

OTHER SIGNIFICANT TRANSACTIONS

OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Tables)	12 Months Ended
	Sep. 30, 2021
SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES
Related party transactions	Warrant No./Class Issue Date No. Warrant Shares Exercise Price Original Expiration Date Amended Expiration Date Clayton Struve Warrant Series C Warrant W98 08-04-2016 1,785,715 $ 0.25 08-04-2021 08-04-2023 Clayton Struve Warrant Series F Warrant F-1 11-14-2016 187,500 $ 0.25 11-13-2021 11-13-2023 Clayton Struve Warrant Series F Warrant F-2 12-19-2016 187,500 $ 0.25 12-18-2021 12-18-2023

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Sep. 30, 2021
INCOME TAXES
Schedule of components of the Company's deferred tax assets	2021 2020 Net operating loss carryforward $ 8,051,000 $ 6,536,000 Stock based compensation 975,000 1,196,000 Intangibles 276,000 305,000 Accruals and reserves 399,000 11,000 Total deferred tax asset 9,701,000 8,048,000 Valuation allowance (9,701,000 ) (8,048,000 ) Net deferred tax assets $ - $ - Change in valuation allowance during the year $ (1,653,000 ) $ (1,092,357 )
Schedule of effective tax rate reconciliation	2021 2020 Income tax provision at statutory rate -21.0 % -21.0 % Warrant interest expense 12 % 9 % Change in valuation allowance 7 % 9 % Prior year true up 2 % 3 % Effective tax rate 0 % 0 %

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
SEGMENT REPORTING
Segment reporting	Segment Operating Segment Segment Revenue (Loss) Assets Three Months Ended June 30, 2022 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ (2,838 ) $ 7,522 Particle, Inc. technology - (23 ) - Digital asset sales - (164 ) 2,105 Total segments $ - $ (3,025 ) $ 9,627 Three Months Ended June 30, 2021 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ (1,719 ) $ 13,993 Particle, Inc. technology - (144 ) 33 Total segments $ - $ (1,863 ) $ 14,026 Segment Operating Segment Segment Revenue Profit (Loss) Assets Nine Months Ended June 30, 2022 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ (7,616 ) $ 7,522 Particle, Inc. technology - (45 ) - Digital asset sales 4,360 923 2,105 Total segments $ 4,360 $ (6,738 ) $ 9,627 Nine Months Ended June 30, 2021 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ (7,088 ) $ 13,993 Particle, Inc. technology - (940 ) 33 Total segments $ - $ 8,028 ) $ 14,026	Gross Operating Segment Segment Revenue Margin (Loss) Assets Year Ended September 30, 2021 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ - $ (9,373 ) $ 12,867 Particle, Inc. technology - - (1,073 ) 22 TransTech distribution business - - - - Total segments $ - $ - $ (10,446 ) $ 12,889 Year Ended September 30, 2020 Development of the Bio-RFID™” and “ChromaID™” technologies $ - $ - $ (5,481 ) $ 4,360 Particle, Inc. technology - - (1,280 ) 322 TransTech distribution business 122 70 (65 ) - Total segments $ 122 $ 70 $ (6,826 ) $ 4,682

SUBSEQUENT EVENT (Tables)

SUBSEQUENT EVENT (Tables)	9 Months Ended
	Jun. 30, 2022
SUBSEQUENT EVENTS
Schedule of extension of warrant agreement	Warrant No./Class Issue Date No. Warrant Shares  Exercise Price  Original Expiration Date Amended Expiration Date Clayton A. Struve Warrant  08-14-2017  1,440,000  $0.25  08-13-2023 08-13-2024 Clayton A. Struve Warrant  12-12-2017  1,200,000  $0.25  12-11-2023 12-11-2024 Clayton A. Struve Warrant 08-04-2016  1,785,715  $0.25  08-04-2023 08-04-2024 Clayton A. Struve Warrant 02-28-2018  1,344,000  $0.25  02-28-2023 02-28-2024

ORGANIZATION (Details Narrative

ORGANIZATION (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2022	Oct. 15, 2021	Sep. 30, 2021	Sep. 30, 2020
ORGANIZATION
Authorized shares of capital common stock	205,000,000		105,000,000	100,000,000
Authorized shares of capital stock par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock shares authorized	5,000,000		5,000,000	5,000,000
Preferred stock share par value	$ 0.001		$ 0.001	$ 0.001
Sales	$ 4,360,087
Authorized common stock increased		200,000,000

LIQUIDITY and GOING CONCERN (De

LIQUIDITY and GOING CONCERN (Details Narrative) - USD ($)		9 Months Ended
	Mar. 15, 2021	Jun. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Sep. 30, 2019
LIQUIDITY and GOING CONCERN
Proceeds of warrants currently outstanding		$ 16,383,908
New offering of shares of its common stock		3
Offering Price		$ 2
Cash and cash equivalents		$ 8,351,945	$ 12,258,218	$ 13,870,183	$ 15,696,579	$ 4,298,179	$ 1,900,836
Working capital		6,042,208	10,092,586
Accumulated deficit		$ (95,827,137)	$ (81,326,494)			$ (55,966,281)
Gross proceeds from private placement	$ 14,209,000
Warrants in private placement to accredited investors	3,552,250
Convertible notes converted into common stock, per share	$ 2
Bear annual interest rate	8%

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Jul. 06, 2022	Mar. 31, 2021	Dec. 15, 2020	Jul. 06, 2020
Total amount of digital asset conversion losses	$ 164,093		$ 3,436,955
FDIC insurance	250,000		250,000		$ 250,000
Research and development expense	1,272,537	$ 868,584	3,406,996	$ 3,094,123	3,969,972	$ 2,033,726
Advertising and marketing costs			514,401	$ 240,000	329,375	230,844
Money market accounts	$ 6,041,016		$ 6,041,016		$ 12,217,714	$ 4,252,959
Common stock shares issued	43,802,147		43,802,147		35,166,551	24,804,874		23,169,587		500,000
Common stock shares outstanding	43,802,147		43,802,147		35,166,551	24,804,874		28,257,467
Issuable upon conversion of convertible debentures	2,255,066		2,255,066		16,124,764	7,894,566		16,464,066
Uninsured deposits					$ 12,008,228	$ 4,048,179
Unearned stock option grants					32,629,376
Common shares current price per share					$ 1.90	$ 1.20	$ 2.24		$ 1.155
Convertible Preferred Stock
Antidilutive securities			8,108,356	8,108,356	8,108,356	8,108,356
Warrants
Antidilutive securities			21,651,513		22,564,255	20,016,367
Stock Option 1
Unearned stock option grants			11,550,745	11,775,745	11,775,745	2,630,000
Antidilutive securities			20,927,370	14,650,120	15,315,120	4,805,000
Leasehold Improvements
Estimated useful lives of assets			5 years		5 years
Minimum
Estimated useful lives of assets			2 years		2 years
Maximum
Estimated useful lives of assets			5 years		5 years
Transaction 1
Common stock shares			9,020,264	9,020,264	9,020,264	9,020,264
Common shares current price per share	$ 0.25		$ 0.25		$ 0.25	$ 0.25		$ 0.25
Transaction 2
Common stock shares			2,255,066	4,924,500	7,104,500	5,639,500
Common shares current price per share					$ 2	$ 1		1
Transaction 3
Common stock shares				7,104,500
Common shares current price per share								$ 2

Artificial Intelligence (AI) _2

Artificial Intelligence (AI) Deep Learning Platform (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Accounts receivable related party		$ (46,146)
Reduction in value, related to the Ethereum	$ 96,820
Accrued expenses	533,993	533,993	$ 893,137	$ 401,178
Received cash	2,908,551	2,908,551
Selling and transactional costs		1,300,000
Artificial Intelligence [Member]
Accounts receivable related party	3,124,581	46,146
Reduction in value, related to the Ethereum	96,820	169,884
Revenue Digital Asset Sales	4,360,087	4,360,087
Accrued expenses	436,378	436,378
Payment to consultant			1,075,000
Received cash	2,908,551	2,908,551
Selling and transactional costs	$ 156,485,200,000	$ 79,935,300,000	$ 1,300,000

FIXED ASSETS (Details)

FIXED ASSETS (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
PROPERTY AND EQUIPMENT
Machinery and equipment (2-3 years)	$ 1,498,355	$ 654,798	$ 355,272
Leasehold improvements (5 years)	3,612	3,612	3,612
Furniture and fixtures (5 years)	26,855	26,855	26,855
Less: accumulated depreciation	(575,444)	(356,761)	(257,068)
Property and equipment, net	$ 953,378	$ 328,504	$ 128,671

FIXED ASSETS (Details Narrative

FIXED ASSETS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
PROPERTY AND EQUIPMENT
Depreciation expense	$ 207,440	$ 10,918	$ 0	$ 64,980	$ 99,693	$ 69,655

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
PROPERTY AND EQUIPMENT
Machinery and equipment (2-3 years)	$ 1,498,355	$ 654,798	$ 355,272
Leasehold improvements (5 years)	3,612	3,612	3,612
Furniture and fixtures (5 years)	26,855	26,855	26,855
Less: accumulated depreciation	(575,444)	(356,761)	(257,068)
Property and equipment, net	$ 953,378	$ 328,504	$ 128,671

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
PROPERTY AND EQUIPMENT
Depreciation expense	$ 207,440	$ 10,918	$ 0	$ 64,980	$ 99,693	$ 69,655

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Technology (3 years)	$ 276,000	$ 305,000
Technology
Technology (3 years)	520,000	520,000
Less: accumulated amortization	(520,000)	(418,886)
Intangible assets, net	$ 0	$ 101,114

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
INTANGIBLE ASSETS
Amortization expense	$ 101,114	$ 173,332
Fair value of intellectual property assocated	$ 520,000

LEASES (Details)

LEASES (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020
LEASES
2022		$ 128,987
2023	$ 156,253	107,662
2024	118,602	73,095
2025		0
2026		0
Total Remaining Payments	274,855	309,744
Imputed interest	(12,629)	(19,203)
Total lease liability	$ 262,226	$ 290,000	$ 290,000	$ 132,000

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
LEASES
Lease cost	$ 130,767	$ 102,741	$ 139,643	$ 136,718
Operating lease right of use asset	262,242	291,000	289,002	129,003
Total lease liability	262,226	$ 290,000	290,000	$ 132,000
Cash paid for ROU operating lease liability	$ 159,112		$ 139,643
Weighted-average remaining lease term	20 years		28 years
Weighted-average discount rate	7%	7%

CONVERTIBLE NOTES PAYABLE AND_3

CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
less conversions of notes	$ (14,209,000)	$ (5,639,500)	$ (4,242,490)
less debt discount - BCF	0	(4,308,337)	(2,127,894)
less debt discount - warrants	0	(1,957,590)	(1,025,512)
less debt discount - warrants issued for services	0	(1,056,984)	(823,582)
Convertible notes, net	2,255,066	9,191,155	3,967,578
Convertible Note - Clayton A. Struve
Convertible notes, gross	1,071,000	1,071,000	1,071,000
Convertible Note - Ronald P. Erickson and Affiliates
Convertible notes, gross	1,184,066	1,184,066	1,184,066
2019 Convertible Notes
Convertible notes, gross	4,242,490	4,242,490	4,242,490
2020 Convertible Notes
Convertible notes, gross	0	5,639,500	5,639,500
Q2 2021 Convertible Notes
Convertible notes, gross	14,209,000	14,209,000	0
Bousted Fee Refund (Originally Booked as Contra Debt)
Convertible notes, gross	$ 0	$ 50,000	$ 50,000

CONVERTIBLE NOTES PAYABLE AND_4

CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative) - USD ($)			1 Months Ended					3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
	Jun. 11, 2022	Feb. 02, 2021	Dec. 31, 2021	Dec. 31, 2020	Apr. 30, 2020	May 31, 2019	Mar. 16, 2018	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2020	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021
Gain on loan forgiveness												$ 253,000
Interest expense								$ 239,760	$ 5,228,058	$ 1,733,738		$ 8,024,709	$ 9,735,604	$ 14,914,065	$ 6,094,682
Issuance costs of debt													$ 727,117	$ 727,117	479,965
Fund raised by convertible debt offerings															$ 2,819,750
Common stock issued related to conversion of convertible notes and interest								2,255,066				2,255,066		16,124,764	7,894,566	16,464,066
Note Payable
Interest expense		$ 1,268										$ 2,721		$ 3,222	$ 960
Proceeds from paycheck protection program loan		$ 205,633			$ 226,170
Note Payable | On April 30, 2020 [Member]
Interest expense											$ 4,350			3,222
Repay of principal amount	$ 78,843											98,106
Repayment of principal Interest Amount	$ 1,057											1,997
Loan balance												128,064
Note Payable | On February 1, 2021 [Member]
Interest expense												2,721		1,268
Convertible Note - Clayton A. Struve
Accrued interest								$ 84,671				84,671		79,062	71,562
Convertible promissory or OID notes								1,071,000				1,071,000		1,071,000
Convertible debt offering invested amount						$ 1,000,000
Convertible Note - Ronald P. Erickson and Affiliates
Fair value of warrants							$ 110,545
Warrant to purchase common stock shares							1,039,666
Accrued interest								$ 269,383				$ 269,383		216,246	$ 145,202
Exercise price of warrants							$ 0.50
Convertible Debt Offering
Issuance costs of debt														727,117
Fair value of warrants														$ 4,439,317
Warrant to purchase common stock shares														492,090
Warrants to purchase common stock equal to percentage rate												50%		50%	50%
Fund raised by convertible debt offerings			$ 24,000,000	$ 24,000,000										$ 14,209,000	$ 5,639,500
Common stock convertible subject to certain adjustments														7,104,500
Warrants exercisable for shares of common stock														3,552,250
Proceeds from convertible notes and warrants														$ 727,117
Warrants issued for services fair value														1,667,281
Debt discount beneficial conversion feature														$ 9,769,683	$ 3,766,074
Common stock issued related to conversion of convertible notes and interest														6,091,960
Common stock conversion price per share														$ 1
Amortization related to debt offerings												$ 7,272,911		$ 13,256,250
Beneficial conversion feature, warrants issued to debt holders and placement agent												$ 4,184,657		$ 5,662,690
Convertible Debt Offering | Minimum
Exercise price of warrants								$ 1.20				$ 1.20		$ 1.20
Gross proceeds percentage by warrant to purchase common stock														2%
Convertible Debt Offering | Maximum
Exercise price of warrants								$ 2.40				$ 2.40		$ 2.40
Gross proceeds percentage by warrant to purchase common stock														8%
Convertible Note - J3E2A2Z Notes
Convertible redeemable promissory note amount							$ 664,233
Convertible redeemable promissory note principal amount							664,233
Convertible Note - J3E2A2Z Account Payable
Convertible redeemable promissory note amount							519,833
Convertible redeemable promissory note principal amount							$ 519,833

SIMPLE AGREEMENTS FOR FUTURE _2

SIMPLE AGREEMENTS FOR FUTURE EQUITY (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended
	Aug. 09, 2021	Oct. 31, 2020	Jul. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Jul. 06, 2022	Mar. 31, 2021	Dec. 15, 2020
Interest expense				$ 239,760	$ 5,228,058	$ 1,733,738	$ 8,024,709	$ 9,735,604	$ 14,914,065	$ 6,094,682
Proceeds from issuance of SAFE							$ 0	$ 340,000	$ 340,000	$ 785,000
Shares issued price per share									$ 1.90	$ 1.20	$ 2.24		$ 1.155
Boustead Securities LLC [Member]
Interest expense									$ 90,000	$ 54,108
Warrant's issued									43,254
Warrant exercisable									$ 2.40
Warrant issued value									$ 70,980
Shares issued price per share									$ 2.40
Simple Agreement for Future Equity ("SAFE")
Warrant's issued									394,332
Warrant exercisable									$ 2.40
Warrant issued value									$ 240,000
Proceeds from issuance of SAFE	$ 1,125,000	$ 55,000	$ 785,000		340,000
Shares issued	480,600	68,750	981,250									68,750
Conversion into common stock converted amount	$ 961,200
Shares issued price per share	$ 2	$ 0.80	$ 0.80						$ 1.641			$ 0.80
Beneficial conversion feature	$ 72,090
Broker fees		$ 4,125	$ 47,100		$ 23,660
Repayment of cash									$ 253,800

EQUITY (Details)

EQUITY (Details)	9 Months Ended
	Jun. 30, 2022 $ / shares shares
Warrant One
Number of warrant shares | shares	1,440,000
Issue date	Aug. 14, 2017
Original Expiration Date	Aug. 13, 2023
Amended Expiration Date	Aug. 13, 2024
Exercise price | $ / shares	$ 0.25
Warrant Two
Number of warrant shares | shares	1,200,000
Issue date	Dec. 12, 2017
Original Expiration Date	Dec. 11, 2023
Amended Expiration Date	Dec. 11, 2024
Exercise price | $ / shares	$ 0.25
Warrant Three
Number of warrant shares | shares	1,785,715
Issue date	Aug. 04, 2016
Original Expiration Date	Aug. 04, 2023
Amended Expiration Date	Aug. 04, 2024
Exercise price | $ / shares	$ 0.25
Warrant Four
Number of warrant shares | shares	1,344,000
Issue date	Feb. 28, 2018
Original Expiration Date	Feb. 28, 2023
Amended Expiration Date	Feb. 28, 2024
Exercise price | $ / shares	$ 0.25

EQUITY (Details 1)

EQUITY (Details 1) - $ / shares	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Shares
Share Outstanding at beginning of period	22,564,255	20,016,367
Issued	60,000	6,608,789
Exercised	(863,986)
Forfeited	0	384,359
Expired	(108,756)
Share Outstanding at ending of period	21,651,513	22,564,255
Exercisable at end of period	21,651,513	22,564,255
Outstanding at begin of period	$ 0.998	$ 1.161
Weighted Average Exercise Price Issued	0	2.117
Weighted Average Exercise Price Exercised	(0.919)
Weighted Average Exercise Price Forfeited	0	1.155
Weighted Average Exercise PriceExpired	(1)	0
Outstanding at ending of period	$ 1.003	$ 0.998
Exercised		(3,676,542)
Forfeited	0	(384,359)
Weighted Average Exercise Price
Exercised		$ (0.582)
Forfeited	$ 0	1.155
Expired	$ 1	$ 0

EQUITY (Details 2)

EQUITY (Details 2) - $ / shares	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021	May 20, 2022	Sep. 30, 2020	Nov. 09, 2019
Number of warrants		15,315,120
Weighted average remaining life (years)		3 years 1 month 24 days
Weighted average exercise price, outstanding		$ 1.316
Shares exercisable		1,720,456
Weighted average exercise price, exercisable		$ 0.80	$ 1.48	$ 2.593	$ 0.25
Warrant One
Number of warrants	10,729,381	10,829,381
Weighted average remaining life (years)	4 years 9 months 14 days	1 year 2 months 26 days
Weighted average exercise price, outstanding	$ 0.250	$ 0.250
Shares exercisable	10,729,381	10,829,381
Weighted average exercise price, exercisable	$ 0.250	$ 0.250
Warrant Two
Number of warrants	6,547,207
Weighted average remaining life (years)	2 years 7 months 2 days
Shares exercisable	6,547,207
Warrant Two | Minimum
Weighted average exercise price, outstanding	$ 1.20
Weighted average exercise price, exercisable	1.20
Warrant Two | Maximum
Weighted average exercise price, outstanding	1.85
Weighted average exercise price, exercisable	$ 1.85
Warrant Three
Number of warrants	4,364,925	847,742
Weighted average remaining life (years)	3 years 9 months 7 days	1 month 13 days
Weighted average exercise price, outstanding		$ 1
Shares exercisable	4,364,925	847,742
Weighted average exercise price, exercisable		$ 1
Warrant Three | Minimum
Weighted average exercise price, outstanding	$ 2
Weighted average exercise price, exercisable	2
Warrant Three | Maximum
Weighted average exercise price, outstanding	2.40
Weighted average exercise price, exercisable	$ 2.40
Warrant Four
Number of warrants	10,000	6,512,207
Weighted average remaining life (years)	1 year	3 years 3 months 25 days
Weighted average exercise price, outstanding	$ 4.080
Shares exercisable	10,000	6,512,207
Weighted average exercise price, exercisable	$ 4.080
Warrant Four | Minimum
Weighted average exercise price, outstanding		$ 1.20
Weighted average exercise price, exercisable		1.20
Warrant Four | Maximum
Weighted average exercise price, outstanding		1.85
Weighted average exercise price, exercisable		$ 1.85
Warrant Total
Number of warrants	21,651,513	22,564,255
Weighted average remaining life (years)	3 years 5 months 4 days	3 years 5 months 26 days
Weighted average exercise price, outstanding	$ 1.003	$ 0.998
Shares exercisable	21,651,513	22,564,255
Weighted average exercise price, exercisable	$ 1.003	$ 0.998
Warrant Five
Number of warrants		4,364,925
Weighted average remaining life (years)		4 years 6 months
Shares exercisable		4,364,925
Warrant Five | Minimum
Weighted average exercise price, outstanding		$ 2
Weighted average exercise price, exercisable		2
Warrant Five | Maximum
Weighted average exercise price, outstanding		2.40
Weighted average exercise price, exercisable		$ 2.40
Warrant Six
Number of warrants		10,000
Weighted average remaining life (years)		1 year 9 months
Weighted average exercise price, outstanding		$ 4.080
Shares exercisable		10,000
Weighted average exercise price, exercisable		$ 4.080

EQUITY (Details 3)

EQUITY (Details 3)	12 Months Ended
	Sep. 30, 2021
Warrants
Dividend yield	0%
Risk free interest rate	0.37%
Expected volatility	140%
Warrant One | Minimum
Expected life	3 years
Warrant One | Maximum
Expected life	5 years

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)					3 Months Ended						9 Months Ended		12 Months Ended
	Feb. 05, 2022	Jan. 05, 2022	Jul. 06, 2020	Jan. 01, 2020	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Jul. 06, 2022	Oct. 15, 2021	Feb. 09, 2021	Jan. 28, 2021	Jan. 15, 2021	Dec. 15, 2020	Nov. 04, 2019	Oct. 04, 2019	Sep. 30, 2019	Sep. 30, 2018
Convertible debt														$ 2,819,750
Warrants totaling													$ 4,487,207	615,675
Net loss					$ (3,003,286)	$ (6,140,738)	$ (5,356,619)	$ (7,090,863)	$ (5,373,618)	$ (5,299,331)	$ (14,500,643)	$ (17,763,812)	(25,360,213)	(13,562,641)
Convertible Notes Payable					$ 2,255,066						$ 2,255,066		$ 16,464,066	$ 9,020,264
Outstanding warrants to purchase					10,284,381						10,284,381
Exercise price													$ 1.90	$ 1.20	$ 2.24					$ 1.155
Intrinsic value											$ 19,956,371		$ 34,314,540
Money warrants											$ 21,651,513		$ 22,554,255
Common stock par value					$ 0.001						$ 0.001		$ 0.001	$ 0.001		$ 0.001
Unearned stock option grants											11,550,745		11,775,745
Preferred stock shares authorized					5,000,000						5,000,000		5,000,000	5,000,000
Preferred stock par value					$ 0.001						$ 0.001		$ 0.001	$ 0.001
Shareholders paid			$ 125,000										$ 125,000
Common stock fair market value														$ 1,045,000
Common stock shares issued			500,000		43,802,147				23,169,587		43,802,147		35,166,551	24,804,874
Common stock restricted shares issued for services													550,000
Loss related to issuance of shares for debt settlement													$ 0	$ 825,000
Price of warrants														$ 0.889
Automatic conversion of Convertible											The Company issued 7,672,860 shares of common stock related to the automatic conversion of Convertible Notes and interest from a private placement to accredited investors in 2021. The Convertible Notes and interested were automatically converted to Common Stock at $2.00 per share on the one year anniversary in March 2022
Common stock shares outstanding					43,802,147				28,257,467		43,802,147		35,166,551	24,804,874
Warrants vested					21,651,513						21,651,513
Intrinsic value					$ 34,066,802			$ 52,105,394	$ 52,105,394		$ 34,066,802	52,105,394	$ 23,964,509	$ 5,580,550									$ 9,180,369	$ 3,706,519
Options to purchase common stock share					20,927,370						20,927,370		15,315,120
Warrant issued to common stock					21,714,023						21,714,023		22,564,255
Conversion of convertible debentures													$ 16,464,066
Common shares													16,124,764	9,020,264
Proceeds from issuance of common stock											$ 153,000	202,820	$ 23,344	$ 0
Authorized common stock increased																200,000,000
Common stock shares authorized					200,000,000						200,000,000		100,000,000	100,000,000
Preferred stock shares outstanding					0						0		0	0
Preferred stock shares issued					0						0		0	0
Warrants initially exercisable											$ 793,986	$ 713,203	$ 1,313,203	$ 85,575
Warrants to Purchase Common Stock [Member]
Exercise price				$ 1.120										$ 0.952
Common stock par value					$ 1						$ 1
Common stock fair market value														$ 507,560
Common stock shares issued					108,756						108,756			733,588
Proceeds from issuance of common stock											$ 766,486
Shrare issued warrant to purchased	20,000	20,000									108,756
Shrare issued warrant to purchased price	$ 1.70	$ 1.70
Warrants expiration period	Jan. 05, 2027
Shares issued					801,486						801,486
November 9, 2019 [Member]
Common stock shares issued														733,588
Common stock shares received														73,191
Exercise price														$ 0.25
Simple Agreements for Future Equity [Member]
Common stock shares issued													480,600
Price of warrants													$ 2
Common stock shares related party													$ 961,200
Warrant [Member]
Proceeds from issuance of common stock											$ 793,986
Shares issued					863,986						863,986
Directors [Member]
Convertible Notes Payable													$ 7,104,500
Exercise price				$ 1.90									$ 1.918						$ 2
Common stock shares issued													3,676,542
Warrant issued to common stock													269,510							2,000,000
Shares issued																			30,000
Preferred stock purchase													$ 384,359
Restricted common stock issued, value				$ 228,000									735,745
Warrants initially exercisable													3,552,250
Boustead Securities LLC [Member]
Convertible Notes Payable													$ 43,254
Exercise price													$ 2.40
Common stock fair market value														$ 1,045,000
Restricted common stock issued, value													$ 1,641
Ronald P. Erickson [Member]
Exercise price				$ 1.90	$ 2.09						$ 2.09		$ 1.53	$ 1.95			$ 0.80	$ 0.25		$ 1.53	$ 1.10	$ 3.03
Warrant issued to common stock					1,000,000						1,000,000		2,000,000	1,770						2,000,000	1,200,000	1,000,000
Restricted common stock issued, value				$ 190,000									$ 1,811,691	$ 75,000
Three Director [Member]
Exercise price																			$ 2
Shares issued	30,000	30,000
Common Stock Shares issued excercised price	$ 1.70	$ 1.70
Three Director [Member] | Warrant [Member]
Shrare issued warrant to purchased	20,000
Shrare issued warrant to purchased price	$ 1.70
Warrants expiration period	Jan. 05, 2027
Series C Convertible Preferred Stock [Member]
Preferred stock shares authorized					1,785,715						1,785,715		1,785,714	1,785,714
Preferred stock par value													$ 0.001
Price of warrants					$ 0.25						$ 0.25		0.25	$ 0.25
Conversion price													$ 0.70	$ 0.70
Preferred stock purchase											$ 1,250,000		$ 1,250,000	$ 1,250,000
Preferred stock yield											8%		8%	8%
Ownership percentage											4.99%		4.99%	4.99%
Warrant expiry											Aug. 04, 2024		Aug. 04, 2023
Price of warrants														$ 0.25
Conversion of stock											8,108,356
Series D Convertible Preferred Stock [Member]
Preferred stock shares authorized					1,016,014						1,016,014		1,016,014	1,016,014
Preferred stock par value					$ 0.001						$ 0.001		$ 0.001	$ 0.001
Conversion price													$ 0.25	$ 0.25
Preferred stock purchase													$ 750,000	$ 750,000
Preferred stock yield											8%		8%	8%
Ownership percentage											4.99%		4.99%	4.99%
Annual yield											8%		8%	8%
Preferred stock shares outstanding					1,016,004						1,016,004		1,016,004	1,016,004
Preferred stock shares issued					1,016,004						1,016,004		1,016,004	1,016,004
Stock at 0.25
Warrants totaling					$ 4,487,207						$ 4,487,207		$ 4,487,207
Price of warrants					$ 0.25						$ 0.25		$ 0.25
Common shares					9,020,264						9,020,264		9,020,264
Adjusting amount of shares, percentage													1.20%
Stock at 2.00
Warrants totaling					$ 3,954,625						$ 3,954,625		$ 3,954,625
Price of warrants													$ 0.25
Common shares													7,104,500
Adjusting amount of shares, percentage													2.40%
Series F Preferred Stock [Member]
Common shares					100,000						100,000		100,000
Description of explosion date of shares											issued and outstanding until the date which is 731 days after the issuance of Series F Preferred Stock (“Explosion Date”), unless a Trigger Event occurs, in which case the Explosion Date shall be extended by 183 days		issued and outstanding until the date which is 731 days after the issuance of Series F Preferred Stock (“Explosion Date”), unless a Trigger Event occurs, in which case the Explosion Date shall be extended by 183 days
Common Preferred Stock [Member]
Convertible Notes Payable													$ 6,091,960
Exercise price													$ 1	$ 1
Common stock fair market value													$ 202,820
Common stock shares issued													3,676,542	4,581,917
Proceeds from issuance of common stock											$ 13,688
Conversion price													$ 0.582	$ 1
Common stock shares related party													97,000
Exercise of stock option											8,750		16,875
Stock option grants per share													$ 1.38
Authorized Capital Stock [Member]
Common stock par value					$ 0.001						$ 0.001		$ 0.001			$ 0.001
Preferred stock shares authorized					5,000,000						5,000,000		5,000,000
Preferred stock par value					$ 0.001						$ 0.001		$ 0.001
Common stock shares issued					200,000,000						200,000,000		100,000,000
Common stock shares outstanding					43,826,781						43,826,781
Conversion of convertible debentures					$ 2,255,066						$ 2,255,066
Common shares					9,020,264						9,020,264		16,124,764	9,020,264
Shares issued					43,826,781						43,826,781
Authorized common stock increased																200,000,000
Common stock shares authorized					205,000,000						205,000,000		105,000,000
Preferred stock shares outstanding					2,801,719						2,801,719
Preferred stock shares issued					2,801,719						2,801,719
Convertible Preferred Stock D [Member]
Conversion price					$ 0.25						$ 0.25		$ 0.25
Preferred stock purchase											$ 750,000		$ 750,000
Preferred stock yield											8%		8%
Ownership percentage											4.99%		4.99%
Annual yield											8%		8%

STOCK INCENTIVE PLANS (Details)

STOCK INCENTIVE PLANS (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Aggregate Intrinsic Value
Outstanding at beginning of period	$ 23,964,509	$ 5,580,550	$ 9,180,369
Granted	11,632,130	18,807,990	3,522,400
Exercised	(13,688)	(28,031)	(18,298)
Forfeitures	(1,516,150)	(396,000)	(7,103,921)
Outstanding at end of period	$ 34,066,802	$ 23,964,509	$ 5,580,550
Outstanding at begin of period	$ 0.998	$ 1.161
Weighted average exercise price exercised		(0.582)
Outstanding at ending of period	$ 1.003	$ 0.998	$ 1.161
Share Outstanding at beginning of period	22,564,255	20,016,367
Shares granted	60,000	6,608,789
Shares exercised		(3,676,542)
Shares forfeited	0	384,359
Share Outstanding at ending of period	21,651,513	22,564,255	20,016,367
Stock Option Activity
Aggregate Intrinsic Value
Share Outstanding at beginning of period	15,315,120	4,805,000	4,532,668
Shares granted	6,446,000	10,650,745	3,085,000
Shares exercised	(8,750)	(20,625)	(73,191)
Shares forfeited	825,000	120,000	2,739,477
Share Outstanding at ending of period	20,927,370	15,315,120	4,805,000
Weighted Average Exercise Price:
Aggregate Intrinsic Value
Outstanding at begin of period	$ 1.565	$ 1.161	$ 2.025
Weighted average exercise price, granted	1.805	1.766	1.142
Weighted average exercise price exercised	(1.564)	(1.359)	(0.250)
Weighted average exercise price forfeited	(1.838)	(3.300)	(2.593)
Outstanding at ending of period	$ 1.628	$ 1.565	$ 1.161

STOCK INCENTIVE PLANS (Details

STOCK INCENTIVE PLANS (Details 1) - $ / shares	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Number of outstanding stock options		15,315,120
Weighted average remaining life (years)		3 years 1 month 24 days
Weighted average exercise price outstanding		$ 1.565
Weighted average exercise price exerciseable		$ 1.316
Number exercisable		1,720,456
Employee Stock Options One [Member]
Number of outstanding stock options	20,927,370
Weighted average remaining life (years)	4 years 1 month 24 days
Weighted average exercise price outstanding	$ 1.628
Weighted average exercise price exerciseable	$ 1.241
Number exercisable	2,590,141
Stock Options 1
Number of outstanding stock options	230,000
Weighted average remaining life (years)	11 months 15 days
Weighted average exercise price outstanding	$ 0.250
Weighted average exercise price exerciseable	$ 0.250
Number exercisable	201,250
Range of exercise prices	$ 0.25
Stock Options 2
Number of outstanding stock options	2,930,625
Weighted average remaining life (years)	2 years 4 months 6 days
Weighted average exercise price outstanding	$ 1.101
Weighted average exercise price exerciseable	$ 1.105
Number exercisable	548,307
Stock Option 3
Number of outstanding stock options	12,330,745
Weighted average remaining life (years)	2 years 5 months 15 days
Weighted average exercise price outstanding	$ 1.503
Weighted average exercise price exerciseable	$ 1.303
Number exercisable	1,175,521
Stock Option 4
Number of outstanding stock options	5,436,000
Weighted average remaining life (years)	4 years 3 months
Weighted average exercise price outstanding	$ 1.195
Weighted average exercise price exerciseable	$ 1.917
Number exercisable	665,063
Minimum | Stock Option 3
Range of exercise prices	$ 1.28	$ 1.28
Minimum | Stock Option 4
Range of exercise prices	1.79	1.79
Maximum | Stock Option 3
Range of exercise prices	1.67	1.53
Maximum | Stock Option 4
Range of exercise prices	3.67	$ 3.67
Stock Option 1
Number of outstanding stock options		230,000
Weighted average remaining life (years)		1 year 8 months 15 days
Weighted average exercise price outstanding		$ 0.250
Weighted average exercise price exerciseable		$ 0.250
Number exercisable		172,500
Range of exercise prices		$ 0.25
Stock Option 2
Number of outstanding stock options		3,074,375
Weighted average remaining life (years)		3 years 6 months 29 days
Weighted average exercise price outstanding		$ 1.108
Weighted average exercise price exerciseable		$ 1.105
Number exercisable		445,456
Stock Option 2 | Minimum
Range of exercise prices	1.10	$ 1.10
Stock Option 2 | Maximum
Range of exercise prices	$ 1.25	$ 1.25
Stock Option 3
Number of outstanding stock options		9,480,745
Weighted average remaining life (years)		3 years 9 months 25 days
Weighted average exercise price outstanding		$ 1.499
Weighted average exercise price exerciseable		$ 1.307
Number exercisable		993,750
Stock Option 4
Number of outstanding stock options		2,530,000
Weighted average remaining life (years)		4 years 7 months 20 days
Weighted average exercise price outstanding		$ 2.192
Weighted average exercise price exerciseable		$ 1.895
Number exercisable		108,750

STOCK INCENTIVE PLANS (Detail_2

STOCK INCENTIVE PLANS (Details Narrative) - USD ($)		1 Months Ended			9 Months Ended		12 Months Ended
	Nov. 09, 2019	May 20, 2022	Feb. 09, 2021	May 21, 2020	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Jul. 06, 2022	Dec. 10, 2021	Oct. 15, 2021	Jan. 28, 2021	Dec. 15, 2020	Nov. 23, 2020	Jan. 01, 2020	Nov. 04, 2019	Oct. 04, 2019	May 22, 2019	Jan. 23, 2019
Compensation expense					$ 1,555,875	$ 570,514	$ 1,028,522	$ 1,702,085
Unrecognized compensation costs					7,065,596		$ 1,312,936
Average exercise price	$ 0.25	$ 1.48					$ 0.80	$ 2.593
Grant					$ 13,688
Share					8,750
Warrant issued to common stock					21,714,023		22,564,255
Unearned stock option grants					11,550,745		11,775,745
Stock option grants		1,000,000						2,739,477
Common stock for vested stock option	73,191
Common stock for vested stock option, totaling	93,750
Period for recognition		5 years					3 years 9 months 25 days
Options to purchase common stock							15,315,120
Exercise price							$ 1.90	$ 1.20	$ 2.24				$ 1.155
Stock options granted							32,629,376
Intrinsic value					$ 19,956,371		$ 34,314,540
Ronald P. Erickson [Member]
Warrant issued to common stock					1,000,000		2,000,000	1,770					2,000,000			1,200,000	1,000,000
Period for recognition					5 years
Exercise price			$ 0.80		$ 2.09		$ 1.53	$ 1.95				$ 0.25	$ 1.53		$ 1.90	$ 1.10	$ 3.03
Stock options granted			500,000
Phillip A. Bosua [Member]
Warrant issued to common stock					1,300,000		1,300,000
Period for recognition					5 years
Exercise price			$ 0.80		$ 2.09		$ 2.09						$ 1.53		$ 1.90	$ 1.10	$ 3.03
Stock options granted			500,000
Stock Option | Employees
Average exercise price							$ 3.30
Stock options granted							120,000
Stock Option | Employees One
Average exercise price							$ 0.80
Stock options granted							550,000
Stock Option | Seventeen Employees And Consultants
Average exercise price							$ 1.766	$ 1.142
Period for recognition							5 years
Stock options granted							15,315,120	3,085,000
Stock option grants, total							9,145,745	2,630,000
Intrinsic value							$ 14,916,905
Stock Option | Two Consultants
Average exercise price					$ 1.699		$ 1.359
Stock options granted					3,146,000		20,625
Stock Option | Seven Employees And Consultants [Member]
Average exercise price					$ 2.09
Period for recognition					5 years
Stock options granted					1,085,000
Stock option granted					20,927,370
Aggregate intrinsic value					$ 22,540,075
Stock option grants, total					17,878,245
Intrinsic value					$ 8,556,635
Stock Option | Four Consultants
Average exercise price					$ 1.838
Stock options granted					825,000
2011 Stock Incentive Plan
Average exercise price					$ 1.651		$ 1.565
Unearned stock option grants					11,550,745		11,775,745
Options to purchase common stock					20,927,370		15,315,120							9,750,000				3,000,000	2,500,000
Average exercise prices					$ 1.628
Stock option grant vests description							(i) 33.3% with the first shipment; (ii) 33.3% with $50 million in sales are achieved; and (iii) 33.4% after $200 million in sales are achieved
2021 Equity Incentive Plan
Unearned stock option grants							1,505,000
Options to purchase common stock											20,000,000
Stock options granted							10,650,745
Stock option grants, total							1,900,000
Repurchased					14,650,120
2011 And 2021 Stock Incentive Plan [Member]
Registered shares issued										34,650,120
Particle, Inc.
Compensation expense							$ 197,553	$ 833,771
Period for recognition				4 years			4 years 1 month 24 days
Options to purchase common stock				8,000,000

SIGNIFICANT AND OTHER TRANSAC_2

SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES (Details)	12 Months Ended
	Sep. 30, 2021 $ / shares shares
Clayton Struve Warrant: Series C Warrant W98
Issue date	08-04-2016
Number of warrant shares | shares	1,785,715
Exercise price | $ / shares	$ 0.25
Original expiration date	08-04-2021
Amended expiration date	08-04-2023
Clayton Struve Warrant: Series F Warrant F-1
Issue date	11-14-2016
Number of warrant shares | shares	187,500
Exercise price | $ / shares	$ 0.25
Original expiration date	11-13-2021
Amended expiration date	11-13-2023
Clayton Struve Warrant: Series F Warrant F-2
Issue date	12-19-2016
Number of warrant shares | shares	187,500
Exercise price | $ / shares	$ 0.25
Original expiration date	12-18-2021
Amended expiration date	12-18-2023

SIGNIFICANT AND OTHER TRANSAC_3

SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES (Details narrative) - USD ($)								1 Months Ended						3 Months Ended	6 Months Ended	8 Months Ended	9 Months Ended		11 Months Ended	12 Months Ended		14 Months Ended
	Feb. 05, 2022	Jan. 05, 2022	Jan. 15, 2021	Dec. 15, 2020	Jul. 02, 2020	Jun. 01, 2020	Jan. 01, 2020	May 20, 2022	Feb. 09, 2021	Jan. 28, 2021	Mar. 18, 2020	Nov. 04, 2019	May 31, 2019	Jun. 30, 2022	Sep. 30, 2021	May 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Aug. 15, 2021	Jul. 06, 2022	Dec. 31, 2021	Oct. 04, 2019
Special bonus compensation																	$ 1,560,000
Account receivable-related parties														$ 46,146			46,146							$ 3,124,581
Sales and use tax																	436,378
Selling and transactional costs																	1,300,000
Amount paid to consultant																	$ 1,075,000
Warrant issued to common stock														21,714,023	22,564,255		21,714,023			22,564,255
Reduction in value, related to the Ethereum														$ 96,820
Accounts receivable related party																	$ 119,210
Accrued expenses														326,378	$ 799,353		326,378			$ 799,353
Received cash														2,908,551			2,908,551
Selling and transactional costs														$ 156,485,200,000			156,485,200,000
Option granted																				32,629,376
Exercise price				$ 1.155											$ 1.90					$ 1.90	$ 1.20		$ 2.24
Period for recognition								5 years												3 years 9 months 25 days
Stock exercised																	$ 13,687	$ 23,344
Warrant [Member]
Shares issued														863,986			863,986
Ronald P. Erickson [Member]
Warrant issued to common stock				2,000,000								1,200,000		1,000,000	2,000,000		1,000,000			2,000,000	1,770				1,000,000
Option granted									500,000
Restricted common stock issued, value							$ 190,000													$ 1,811,691	$ 75,000
Restricted common stock issued							100,000
Exercise price				$ 1.53			$ 1.90		$ 0.80	$ 0.25		$ 1.10		$ 2.09	$ 1.53		$ 2.09			$ 1.53	$ 1.95				$ 3.03
Period for recognition																	5 years
Salary per month						$ 10,000
Description of particle issued a stock option					Particle issued a stock option grant for 1,500,000 shares at $0.10 per share to Ronald P. Erickson. The stock option grant vests (i) 33.3% upon issuance; (ii) 33.3% after the first sale; and (iii) 33.4% after one million in sales are achieved
Accrued Compensation														46,146	421,599		46,146			421,599
Annual Salary															$ 300,000	$ 195,000	$ 120,000		$ 215,000			$ 120,000
Accrued compensation, travel and interest																				$ 421,599	$ 597,177
Salaries															272,500					272,500
Term period				5 years
Accounts payable and accrued liabilities															$ 421,599					$ 421,599	597,177
Ronald P. Erickson [Member] | Tranche One [Member]
Sales achieved upto									$ 50,000,000
Ronald P. Erickson [Member] | Tranche Two [Member]
Sales achieved upto									$ 200,000,000
Ronald P. Erickson [Member] | Stock Option 2
Option granted				1,865,675
Exercise price				$ 1.53
Term period				5 years
Ronald P. Erickson [Member] | Stock Option 1
Option granted				1,865,675
Exercise price				$ 1.53
Term period				5 years
Phillip A. Bosua [Member]
Warrant issued to common stock														1,300,000	1,300,000		1,300,000			1,300,000
Option granted									500,000
Restricted common stock issued, value							$ 285,000
Restricted common stock issued							150,000
Exercise price				$ 1.53			$ 1.90		$ 0.80			$ 1.10		$ 2.09	$ 2.09		$ 2.09			$ 2.09					$ 3.03
Period for recognition																	5 years
Cancelled a stock option grant																									1,000,000
Stock option grant												1,200,000
Salary per month						$ 10,000
Description of particle issued a stock option					Particle issued a stock option grant for 1,500,000 shares at $0.10 per share to Philip A. Bosua. The stock option grant vests (i) 33.3% upon issuance; (ii) 33.3% after the first sale; and (iii) 33.4% after one million in sales are achieved
Bonus																				$ 250,000
Accrued liabilities related party															$ 250,000					250,000
Annual Salary															350,000					240,000	$ 260,000	$ 120,000
Phillip A. Bosua [Member] | Tranche One [Member]
Sales achieved upto									$ 50,000,000
Phillip A. Bosua [Member] | Tranche Two [Member]
Sales achieved upto									$ 200,000,000
Phillip A. Bosua [Member] | Stock Option 2
Option granted				2,132,200
Exercise price				$ 1.53
Term period				5 years
Phillip A. Bosua [Member] | Stock Option 1
Option granted				2,132,195
Exercise price				$ 1.53
Term period				5 years
Clayton Struve Warrant [Member]
Exercise price										$ 0.25
Accrued Interest														$ 84,671	79,062		$ 84,671			79,062
Convertible promissory notes														$ 1,071,000	$ 1,071,000		$ 1,071,000			$ 1,071,000
Stock exercised										$ 889,880
Directors [Member]
Warrant issued to common stock				2,000,000											269,510					269,510
Restricted common stock issued, value							$ 228,000													$ 735,745
Restricted common stock issued							120,000
Exercise price			$ 2				$ 1.90								$ 1.918					$ 1.918
Shares issued			30,000
Three Director [Member]
Exercise price			$ 2
Shares issued	30,000	30,000
Common Stock Shares issued excercised price	$ 1.70	$ 1.70
Number of warrants issued			20,000
Three Director [Member] | Warrant [Member]
Shrare issued warrant to purchased	20,000
Warrants expiration period	Jan. 05, 2027
Shrare issued warrant to purchased price	$ 1.70
Two Directors [Member]
Exercise price												$ 1.10
Number of warrants issued												105,000
Mr. Struve [Member]
Common shares issued											1,080,000
Invested in debt													$ 1,000,000
Conversion of common stock in debt											$ 1,000,000

COMMITMENTS, CONTINGENCIES AND

COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Details Narrative) - USD ($)

1 Months Ended

6 Months Ended

8 Months Ended

9 Months Ended

11 Months Ended

12 Months Ended

14 Months Ended

May 13, 2022

Feb. 01, 2019

Apr. 10, 2018

Apr. 13, 2017

Oct. 31, 2021

Oct. 11, 2021

Sep. 30, 2021

May 31, 2020

Jun. 30, 2022

Mar. 31, 2021

Sep. 30, 2021

Sep. 30, 2020

Aug. 15, 2021

Leases, net monthly payment

$ 8,697

$ 3,334

$ 2,986

$ 5,000

Lease description

The lease expires on June 30, 2024

lease expires on May 31, 2022

we extended the lease from June 1, 2022 to May 31, 2023 at $2,986 per month

the Company entered into First Amendment of Lease and added 1,030 square feet for year for $5,000 per month. The space will be utilized for clinical trials.

Mr. Bosua

Base Salary

$ 225,000

Common stock shares received

500,000

Common stock per shares

$ 0.33

Ronald P. Erickson [Member]

Annual salary

$ 300,000

$ 195,000

$ 120,000

$ 215,000

$ 120,000

Phillip A. Bosua [Member]

Annual salary

$ 350,000

$ 240,000

$ 260,000

$ 120,000

Peter Conley Vice President [Member]

Base Salary

$ 300,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
INCOME TAXES
Net operating loss carryforward	$ 8,051,000	$ 6,536,000
Stock based compensation	975,000	1,196,000
Intangibles	276,000	305,000
Accruals and reserves	399,000	11,000
Total deferred tax asset	9,701,000	8,048,000
Valuation allowance	(9,701,000)	(8,048,000)
Net deferred tax assets	0	0
Change in valuation allowance during the year	$ (1,653,000)	$ (1,092,357)

INCOME TAXES (Details 1)

INCOME TAXES (Details 1)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Increase in Income Taxes Resulting from:
Income tax provision at statutory rate	(21.00%)	(21.00%)
Warrant interest expense	12%	9%
Change in valuation allowance	7%	9%
Prior year true up	2%	3%
Effective tax rate	0%	0%

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
INCOME TAXES
Loss before tax	$ 6.5	$ 5.1
Deferred tax asset, gross	9.7	$ 8
Net operating loss carryforwards	$ 43.8
Net operating loss carryforwards, expiration dates	2028-2041

SEGMENT REPORTING (Details)

SEGMENT REPORTING (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Revenue	$ 0	$ 0	$ 4,360,000	$ 0	$ 0	$ 122,000
Segment Operating Profit (Loss)	(3,025,000)	(1,863,000)	(6,738,000)	(8,028,000)
Gross margin					0	70,000
Segment assets	9,627,000	14,026,000	9,627,000	14,026,000	12,889,000	4,682,000
Development of the Bio-RFID and ChromaID Technologies
Revenue	0	0	0	0	0	0
Segment Operating Profit (Loss)	(2,838,000)	(1,719,000)	(7,616,000)	(7,088,000)	(9,373,000)	(5,481,000)
Gross margin					0	0
Segment assets	7,522,000	13,993,000	7,522,000	13,993,000	12,867,000	4,360,000
Particle, Inc. Technology
Revenue	0	0	0	0	0	0
Segment Operating Profit (Loss)	(23,000)	(144,000)	(45,000)	(940,000)	(1,073,000)	(1,280,000)
Gross margin					0	0
Segment assets	0	$ 33,000	0	$ 33,000	22,000	322,000
TransTech Distribution Business
Revenue					0	122,000
Segment Operating Profit (Loss)					0	(65,000)
Gross margin					0	70,000
Segment assets					$ 0	$ 0
Digital asset sales [Member]
Revenue	0		4,360,000
Segment Operating Profit (Loss)	(164,000)		1,088,000
Segment assets	$ 2,105,000		$ 2,105,000

SEGMENT REPORTING (Details Narr

SEGMENT REPORTING (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
SEGMENT REPORTING
Non-cash expenses	$ 9,242,544	$ 12,203,424	$ 3,979,584	$ 2,990,072

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Jul. 06, 2022

Oct. 11, 2021

Apr. 13, 2017

Apr. 27, 2022

Dec. 16, 2021

Oct. 31, 2021

Feb. 01, 2021

Apr. 30, 2020

Feb. 01, 2019

Jun. 30, 2022

Jun. 30, 2021

Dec. 31, 2020

Mar. 31, 2022

Jun. 30, 2022

Jun. 30, 2021

Sep. 30, 2021

Sep. 30, 2020

Oct. 15, 2021

Dec. 15, 2020

Common stock shares reserved for future issuance

150,000

Exercise price

$ 2.24

$ 1.90

$ 1.20

$ 1.155

Term

five years

Proceeds from notes payable

$ 0

$ 14,209,000

$ 14,209,000

$ 5,639,500

Interest expense

$ 239,760

$ 5,228,058

$ 1,733,738

8,024,709

9,735,604

14,914,065

6,094,682

Loan interest

$ 0

$ 0

18,800

$ 0

Common stock shares issued upon exercise of stock options/warrants, shares

863,986

Warrant and stock option [Member]

Common stock shares issued upon exercise of stock options/warrants, amount

$ 768,830

Common stock shares issued upon exercise of stock options/warrants, shares

803,361

Note Payable-PPP Loans [Member]

Proceeds from notes payable

$ 205,633

$ 226,170

Interest expense

$ 4,350

$ 3,222

Repayment loan

$ 98,106

Loan interest

1,997

Loan amount forgiven

$ 128,064

Lease modification, pine street [Member]

Lease expiration date

Jun. 30, 2024

Lease periodic payments, payable under agreement

$ 8,697

Change in rental payments, each year, percentage

3%

First amendment to lease, description

the Company entered into First Amendment of Lease and added 1,030 square feet for year for $1,000 for $5,000 per month.

Lease modification, union street [Member]

Lease expiration date

May 31, 2022

May 31, 2023

Lease periodic payments, payable under agreement

$ 3,334

$ 2,986

Change in rental payments, each year, percentage

3%

2021 Equity Incentive Plan [Member]

Common stock shares reserved for future issuance

20,000,000

2021 And 2011 Equity Incentive Plan [Member]

Common stock issued under incentive plans

34,650,120

Ronald P. Erickson [Member]

Common stock shares reserved for future issuance

1,000

Exercise price

$ 2.09

Term

5 years

Phillip A. Bosua [Member]

Common stock shares reserved for future issuance

1,300,000

Exercise price

$ 2.09

Term

5 years

Three directors [Member]

Common stock shares reserved for future issuance

30,000

Number of warrants issued

20,000

Seven employees and three consultants [Member]

Common stock shares reserved for future issuance

910,000

Exercise price

$ 2.09

Term

5 years